



Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner,¹ Andrew H. Wei,² Frederick R. Appelbaum,³ Charles Craddock,⁴ Courtney D. DiNardo,⁵ Hervé Dombret,⁶ Benjamin L. Ebert,⁷ Pierre Fenau,⁸ Lucy A. Godley,⁹ Robert P. Hasserjian,¹⁰ Richard A. Larson,¹¹ Ross L. Levine,¹² Yasushi Miyazaki,¹³ Dietger Niederwieser,¹⁴ Gert Ossenkoppele,¹⁵ Christoph Röllig,¹⁶ Jorge Sierra,¹⁷ Eytan M. Stein,¹⁸ Martin S. Tallman,¹⁸ Hwei-Fang Tien,¹⁹ Jianxiang Wang,²⁰ Agnieszka Wierzbowska,²¹ and Bob Löwenberg²²

¹Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany; ²Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; ³University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA; ⁴Centre for Clinical Haematology, Queen Elizabeth Hospital, University of Birmingham, Birmingham, UK; ⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; ⁶Department of Hematology, Saint-Louis Institute for Research, Université de Paris, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; ⁷Dana-Farber Cancer Institute, Boston, MA; ⁸Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; ⁹Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL; ¹⁰Department of Pathology, Massachusetts General Hospital, Boston, MA; ¹¹Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL; ¹²Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; ¹³Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan; ¹⁴University of Leipzig, Leipzig, Germany; ¹⁵Department of Haematology, Amsterdam UMC, Location VU University Medical Center, Amsterdam, The Netherlands; ¹⁶Department of Internal Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany; ¹⁷Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ¹⁸Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; ¹⁹Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; ²⁰Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; ²¹Department of Hematology, Medical University of Lodz, Lodz, Poland; and ²²Department of Hematology, Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute, Rotterdam, The Netherlands

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease

classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

Introduction

Since the 2017 report from the European LeukemiaNet (ELN),¹ there has been substantial progress in our knowledge of acute myeloid leukemia (AML). Recent advances significantly influence clinical practice. These advances include insights into the clinical value of genomic abnormalities for diagnosis and prognosis, the clinical significance of inherited predisposition to AML, technological advancements in the quantitative assessment of measurable residual disease (MRD) and their utility for assessing therapeutic response and disease risk, the development of a range of novel therapeutic agents, and developments in allogeneic hematopoietic cell transplantation (HCT), resulting in new disease classification,² diagnostic and prognostic algorithms, and updated therapeutic practices. The current report highlights these advances and updates their implications for the standard of care and for clinical trials in AML.

Methods

The panel included international members with recognized clinical and research expertise in AML. Literature and relevant abstract review, categorization of evidence, and arrival at consensus recommendations were developed as previously reported.^{1,3} For diagnosis and management of acute promyelocytic leukemia (APL), readers are referred to the respective recommendations.⁴

AML classification Molecular landscape

Somatic mutations drive the development of AML. Although the epigenetic state of leukemia cells, the bone marrow microenvironment, the health of normal hematopoietic cells, and other

features are important for leukemia biology, somatic mutations can be assessed readily with current techniques. Leukemia develops from the serial acquisition of somatic mutations in hematopoietic stem and progenitor cells with the capacity to self-renew and propagate the neoplastic clone.^{5,6} Initiating mutations may lead to an expanded clone of cells that is apparent in the peripheral blood, termed clonal hematopoiesis, a common pre-malignant state that increases in prevalence with age.⁷ Although some mutations, such as those in *DNMT3A*, *TET2*, and *ASXL1*, are more common in clonal hematopoiesis and appear to be relatively early events in leukemogenesis, others tend to be acquired later in the course of leukemia development, including mutations in *FLT3*, *NRAS*, and *RUNX1*. The combinations of mutations that ultimately drive leukemogenesis are influenced by biological cooperativity and mutual exclusivity between mutated genes.

General classification

The International Consensus Classification of AML^{2,8} that updated the prior revised fourth edition World Health Organization (WHO) classification of AML⁹ introduced changes in the blast thresholds and new genetic entities to define AML, further expanding the spectrum of classification identified by cytogenetic and mutational profiles (Table 1). Because of their overriding impact on disease phenotype and disease outcome, genetic aberrations are given priority in defining AML disease classification, with additional predisposing features (therapy-related, prior myelodysplastic syndrome [MDS] or MDS/myeloproliferative neoplasm [MPN], germline predisposition) appended as qualifiers of the primary diagnosis. A summary of the hierarchical classification is depicted in Figure 1.

Changes to the blast thresholds defining AML

All recurrent genetic abnormalities (Table 1) that define specific subtypes of AML, with the exception of AML with t(9;22)(q34.1;q11.2)/*BCR::ABL1*, are now considered to establish a diagnosis of AML if there are $\geq 10\%$ blasts in the bone marrow or blood. The clinical behavior of myeloid neoplasms with these rearrangements reflects the specific genetic abnormality, even for cases presenting with $<20\%$ blasts.¹⁰⁻¹⁸ This 10% blast threshold aligns with previously AML-defining abnormalities, such as *PML::RARA*, *CBFB::MYH11*, and *RUNX1::RUNX1T1*.¹⁹ To avoid potential overlap with chronic myeloid leukemia in accelerated phase, AML with *BCR::ABL1* still requires $\geq 20\%$ blasts.

Although all other AML subtypes require $\geq 20\%$ blasts for diagnosis, a new category of MDS/AML has been introduced in association with defined genomic abnormalities to include cases with 10% to 19% blasts in the bone marrow or blood to recognize the fact that these cases lie on the border between AML and MDS in terms of their biology and prognosis (Table 1).²⁰⁻²⁵ Patients diagnosed with MDS/AML should be eligible for either MDS or AML clinical trials and treatment approaches.

Antecedent AML history

An important change to the classification is the removal of the former categories AML with myelodysplasia-related changes (AML-MRC) and therapy-related myeloid neoplasms. Recent data indicate that genetic characteristics, rather than clinical history (de novo, secondary after an antecedent MDS or MDS/

MPN, or therapy-related), have most relevance in classifying biologically distinct AML subgroups.^{6,26} Dysplastic morphology, currently used as a criterion for AML-MRC, lacks independent prognostic significance.²⁷⁻²⁹ Thus, although a prior history of MDS or MDS/MPN and prior exposure to therapy are still important features to note in the diagnosis, they are now applied as diagnostic qualifiers to the AML-defining category (Table 1; Figure 1).

AML with recurrent genetic abnormalities

This category has been expanded to include additional variant translocations involving *RARA*, *KMT2A*, and *MECOM*, as well as other rare recurring translocations, which are now recognized as AML-defining entities (Table 1).^{14,30,31} Recent studies show that in-frame mutations affecting the basic leucine zipper (bZIP) region of *CEBPA* confer a favorable outcome, irrespective of their occurrence as biallelic or monoallelic mutations.³²⁻³⁵ In-frame bZIP variants are found in 90% and 35% of cases with biallelic and monoallelic *CEBPA* mutations, respectively. Gene expression analyses support a distinct biology associated with *CEBPA* bZIP mutation in AML. Accordingly, this AML subtype has been redefined to only require an in-frame bZIP *CEBPA* mutation for classification rather than the previous requirement for biallelic *CEBPA* abnormalities.

AML with mutated *TP53*, AML with myelodysplasia-related gene mutations, and AML with myelodysplasia-related cytogenetic abnormalities

Accumulating evidence indicates that from both a clinical and molecular perspective, *TP53*-mutant AML and MDS represent a distinct disease entity. The vast majority of *TP53*-mutant cases have complex karyotypes, and in about half, *TP53* mutations occur in the absence of other AML-associated gene mutations. Clinically, these myeloid neoplasms are associated with a very poor prognosis.^{6,36-41} The presence of a pathogenic *TP53* mutation (at a variant allele fraction of at least 10%, with or without loss of the wild-type *TP53* allele) defines the new entity AML with mutated *TP53*.

Cases lacking *TP53* mutation, but with mutations in *ASXL1*, *BCOR*, *EZH2*, *RUNX1*, *SF3B1*, *SRSF2*, *STAG2*, *U2AF1*, and/or *ZRSR2*, are categorized as AML with myelodysplasia-related gene mutations, irrespective of any prior history of MDS. These mutations are highly associated with AML following prior MDS or MDS/MPN and confer an adverse prognosis even if they occur in de novo AML.^{6,26,42-45} AML with myelodysplasia-related gene mutations encompasses the prior provisional category of AML with mutated *RUNX1*.

The new category AML with myelodysplasia-related cytogenetic abnormalities now includes cases previously classified as AML-MRC due to the presence of myelodysplasia-associated cytogenetic findings, but lacking *TP53* or myelodysplasia-related gene mutations.⁴⁶

Of note, the classification is hierarchical (Figure 1); ie, "AML with mutated *TP53*" takes precedence over "AML with myelodysplasia-related gene mutations," and the latter supercedes "AML with myelodysplasia-related cytogenetic abnormalities."




Figure 1. Hierarchical classification of the International Consensus Classification of AML. The classification is hierarchical (ie, AML with recurrent genetic abnormalities takes precedence over all other categories); among the remaining categories, AML with mutated *TP53* supersedes AML with myelodysplasia-related gene mutations, and the latter supersedes AML with myelodysplasia-related cytogenetic abnormalities. ^aMyeloblasts, monoblasts, and megakaryoblasts are included in the blast count. Monoblasts and promonocytes, but not abnormal monocytes, are counted as blast equivalents in AML with monocytic or myelomonocytic differentiation, and promyelocytes in the setting of *PML::RARA* or variant *RARA* rearrangement. Cases with prior diagnosis of MPN are excluded and are classified as accelerated (10%–19% blasts) or blast phase (≥20% blasts) MPN. For patients who already have a history of MDS/MPN (eg, CMML), the diagnosis of MDS/MPN should be retained until there are ≥20% blasts/blast equivalents; however, once an AML-defining recurrent genetic abnormality (eg, *KMT2A* rearrangement or *NPM1* mutation) is detected and the blast count is ≥10%, AML-type therapy is recommended. ^bAML-defining recurrent genetic abnormalities are *t(15;17)(q24.1;q21.2)/PML::RARA*; *t(8;21)(q22;q22.1)/RUNX1::RUNX1T1*; *inv(16)(p13.1;q22) or t(16;16)(p13.1;q22)/CBFB::MYH11*; *t(9;11)(p21.3;q23.3)/MLLT3::KMT2A*; *t(6;9)(p22.3;q34.1)/DEK::NUP214*; *inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EV11)*; mutated *NPM1*; in-frame bZIP mutated *CEBPA*; *t(9;22)(q34.1;q11.2)/BCR::ABL1*; other recurrent rearrangements involving *RARA*, *KMT2A*, *MECOM*, and other rare rearrangements as listed in Table 1. The entity is named with the specific genetic abnormality. Cases with *BCR::ABL1* rearrangement and 10% to 19% blasts are classified as CML in accelerated phase, and cases with history of CML and ≥20% blasts are classified as CML in myeloid blast phase. ^cExamples how to append diagnostic qualifiers: AML with myelodysplasia-related cytogenetic abnormality, therapy-related; AML with myelodysplasia-related gene mutation, prior myelodysplastic syndrome; AML with myelodysplasia-related gene mutation, germline *RUNX1* mutation (ie, gene or syndrome should be specified).

The remaining AML cases are categorized as “AML, not otherwise specified” (irrespective of the presence or absence of multilineage dysplasia). The 4 categories described above are designated as AML/MDS if the bone marrow or blood blast count is 10% to 19% and as AML with ≥20% blasts (Table 1; Figure 1). Cases that have both a specific AML-defining recurrent genetic abnormality and *TP53* mutation and/or myelodysplasia-related gene mutations or cytogenetics should be classified according to the defined recurrent genetic abnormality. Although complex karyotypes and certain co-mutation profiles confer adverse prognosis to some genetic AML subtypes, these are captured in the prognostic stratification scheme and do not affect their primary diagnostic classification.

Therapy-related AML

Currently comprising 10% to 15% of all newly diagnosed AML, the incidence of cases showing relatedness to previous therapy for another disease continues to rise due in part to increasing

numbers of cancer survivors at risk.⁴⁷ As mentioned above, “therapy-related AML” is no longer considered a disease entity, but the term “therapy-related” is now used as a diagnostic qualifier to the disease entities that are primarily defined by their genetic profile.

These neoplasms have been thought to be the direct consequence of mutational events induced by cytotoxic therapy and/or selection of chemotherapy-resistant clones.^{48–50} In general, these AMLs are associated with adverse genetic lesions, and more than 90% show an abnormal karyotype.^{51,52} The more common subtype, seen in ~75% of cases, typically presents 5 to 7 years after first exposure to alkylating agents or radiation, is often preceded by MDS, and is frequently accompanied by chromosome 5 and/or 7 abnormalities, complex karyotype, and *TP53* mutations.^{48,49,52,53} Some individuals develop AML after treatment with topoisomerase II inhibitors, with breakage at topoisomerase II sites leading to abnormal recombination and balanced translocations involving *KMT2A* at 11q23.3, *RUNX1* at

Table 1. AML and related neoplasms and acute leukemias of ambiguous lineage

AML and related neoplasms	
AML with recurrent genetic abnormalities (requiring $\geq 10\%$ blasts in BM or PB)* <ul style="list-style-type: none"> • APL with t(15;17)(q24.1;q21.2)/PML::RARA† • AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 • AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 • AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A‡ • AML with t(6;9)(p22.3;q34.1)/DEK::NUP214 • AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EV11)§ • AML with other rare recurring translocations • AML with mutated NPM1 • AML with in-frame bZIP mutated CEBPA¶ • AML with t(9;22)(q34.1;q11.2)/BCR::ABL1* 	Myeloid sarcoma Acute leukemia of ambiguous lineage <ul style="list-style-type: none"> • Acute undifferentiated leukemia • MPAL with t(9;22)(q34.1;q11.2)/BCR::ABL1 • MPAL with t(v;11q23.3)/KMT2A-rearranged • MPAL, B/myeloid, not otherwise specified • MPAL, T/myeloid, not otherwise specified
Categories designated AML (if $\geq 20\%$ blasts in BM or PB) or MDS/AML (if 10-19% blasts in BM or PB) <ul style="list-style-type: none"> • AML with mutated TP53# • AML with myelodysplasia-related gene mutations Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 • AML with myelodysplasia-related cytogenetic abnormalities** • AML not otherwise specified 	Myeloid proliferations related to Down syndrome <ul style="list-style-type: none"> • Transient abnormal myelopoiesis associated with Down syndrome • Myeloid leukemia associated with Down syndrome Blastic plasmacytoid dendritic cell neoplasm
Diagnostic qualifiers†† Therapy-related‡‡ <ul style="list-style-type: none"> • Prior chemotherapy, radiotherapy, immune interventions Progressed from MDS <ul style="list-style-type: none"> • MDS should be confirmed by standard diagnostics and >3 mo prior to AML diagnosis Progressed from MDS/MPN (specify type) <ul style="list-style-type: none"> • MDS/MPN should be confirmed by standard diagnostics and >3 mo prior to AML diagnosis Germline predisposition (specify type)	

Classification adopted from reference 2. BM, bone marrow; MPAL, mixed phenotype acute leukemia.

*Bone marrow or peripheral blood blast count of $\geq 10\%$ required, except for AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 which requires bone marrow or peripheral blood blast count of $\geq 20\%$ due to its overlap with progression of chronic myeloid leukemia, BCR::ABL1-positive.

†Other recurring translocations involving RARA should be reported accordingly: eg, APL with t(1;17)(q42.3;q21.2)/IRF2BP2::RARA; APL with t(5;17)(q35.1;q21.2)/NPM1::RARA; APL with t(11;17)(q23.2;q21.2)/ZBTB16::RARA; APL with cryptic inv(17) or del(17)(q21.2q21.2)/STAT5B::RARA; STAT3::RARA; other genes rarely rearranged with RARA: TBL1XR1 (3q26.3); FIP1L1 (4q12); BCOR (Xp11.4).

‡Other recurring translocations involving KMT2A should be reported accordingly: eg, AML with t(4;11)(q21.3;q23.3)/AFF1::KMT2A; AML with t(6;11)(q27;q23.3)/AFDN::KMT2A; AML with t(10;11)(p12.3;q23.3)/MLLT10::KMT2A; AML with t(10;11)(q21.3;q23.3)/TET1::KMT2A; AML with t(11;19)(q23.3;p13.1)/KMT2A::ELL; AML with t(11;19)(q23.3;p13.3)/KMT2A::MLLT1.

§Other recurring translocations involving MECOM should be reported accordingly: eg, AML with t(2;3)(p11~23;q26.2)/MECOM::?; AML with t(3;8)(q26.2;q24.2)/MYC, MECOM; AML with t(3;12)(q26.2;p13.2)/ETV6::MECOM; AML with t(3;21)(q26.2;q22.1)/MECOM::RUNX1.

||Other rare recurring translocations: AML with t(1;3)(p36.3;q21.3)/PRDM16::RPN1; AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA; AML with t(3;5)(q25.3;q35.1)/NPM1::MLF1; AML with t(5;11)(q35.2;p15.4)/NUP98::NSD1; AML with t(7;12)(q36.3;p13.2)/ETV6::MNX1; AML with t(8;16)(p11.2;p13.3)/KAT6A::CREBBP; AML with t(10;11)(p12.3;q14.2)/PICCALM::MLLT10; AML with t(11;12)(p15.4;p13.3)/NUP98::KMD5A; AML with NUP98 and other partners; AML with t(16;21)(p11.2;q22.2)/FUS::ERG; AML with t(16;21)(q24.3;q22.1)/RUNX1::CBFA2T3; AML with inv(16)(p13.3;q24.3)/CBFA2T3::GLIS2.

¶AML with in-frame mutation in the bZIP domain of the CEBPA gene, either monoallelic or biallelic.

#The presence of a pathogenic somatic TP53 mutation (at a variant allele fraction of at least 10%, with or without loss of the wild-type TP53 allele) defines the entity AML with mutated TP53.

**Cytogenetic abnormalities sufficient for the diagnosis of AML with MDS-related cytogenetic abnormalities and the absence of other AML-defining disease categories. Complex karyotype: ≥ 3 unrelated chromosome abnormalities in the absence of other class-defining recurring genetic abnormalities; excludes hyperdiploid karyotypes with three or more trisomies (or polysomies) without structural abnormalities. Unbalanced clonal abnormalities: del(5q)/t(5q)/add(5q); -7/del(7q); +8; del(12p)/t(12p)/(add)(12p); i(17q), -17/add(17p) or del(17p); del(20q); and/or idic(X)(q13).

††Examples: AML with myelodysplasia-related cytogenetic abnormality, therapy-related; AML with myelodysplasia-related gene mutation, prior myelodysplastic syndrome; AML with myelodysplasia-related gene mutation, germline RUNX1 mutation.

‡‡Prior therapy for nonmyeloid neoplasms.

21q22.1, or RARA at 17q21.2. In these cases, the latency period is shorter, often it is only 1 to 3 years, and antecedent MDS is rare.

Another pathogenetic pathway is represented by cases with a preexisting myeloid clone that is resistant to chemotherapy.⁵² Clonal hematopoiesis of indeterminate potential may be the first step in a multi-hit model.^{54,55} Cases were identified in which the exact TP53 mutation found at diagnosis was already present at low frequency in blood or bone marrow many years before AML development.⁵² These data suggest a model in which hematopoietic stem cells carrying mutations in TP53 or PPM1D undergo positive selection by cytotoxic therapy, ultimately leading to AML.^{56,57} Mutations in the RAS/MAPK pathway, alterations in RUNX1 or TP53, and KMT2A rearrangements are also

frequent somatic drivers in pediatric AML related to previous therapy, but unlike in adults, most cases appear to represent independent clones arising as a consequence of cytotoxic therapy and not preexisting minor clones.⁵⁰

Deleterious mutations typical of familial cancer predisposition syndromes in the homologous recombination DNA repair pathway, particularly BRCA1, BRCA2, PALB2, TP53, or CHEK2, are observed in $\sim 20\%$ of cases.^{58,59} The identification of such preexisting conditions facilitates screening and counseling of patients prior to treatment of their primary disease, family donor selection for allogeneic HCT, cancer/organ surveillance strategies, and cascade testing within families.⁶⁰

Germline predisposition

Increasingly, individuals are being recognized as having an inherited germline predisposition to hematopoietic malignancies (Table 2).^{61,62} Recognition of such hereditary predispositions impacts patient management, especially if there is consideration for an allogeneic HCT and health surveillance strategies for the patient and relatives who share the causative variant. Clinical testing for these syndromes is difficult for most clinicians given their relative lack of experience regarding these conditions, requirement for obtaining germline DNA for testing (Table 3), and a lack of standardization in the field regarding which patients and which genes should be tested.⁶³

Germline predisposition risk should be considered for all patients diagnosed with a hematopoietic malignancy regardless of age, because some germline predisposition alleles, like those in *DDX41*, can drive hematopoietic malignancies in older age.^{64,65} When identified, germline predisposing disorders should be applied as diagnostic qualifiers to the specific AML disease category. Key features of the clinical presentation that should prompt consideration of germline testing are given in Table 3. Clinicians should familiarize themselves with academic and commercial testing options, including the culture and sequencing of skin fibroblasts, thereby excluding somatic mutations in hematopoietic cells, and the panel of genes to be analyzed (Table 2).⁶³ Germline variants are categorized as pathogenic, likely pathogenic, variant of uncertain significance, likely benign, or benign; only pathogenic and likely pathogenic variants are considered causative of disease and are followed clinically in families. However, gene variant classification can change over time as additional information regarding gene/allele function and/or segregation data from families becomes available, and variants of uncertain significance in particular are often reclassified as likely pathogenic or pathogenic.

Certain germline disorders are associated with specific characteristics that are important for clinicians to recognize (Table 2), those associated with quantitative and qualitative platelet defects: *ANKRD26*, *ETV6*, and *RUNX1*, and those associated with other organ dysfunction: *GATA2* with immunodeficiency; Shwachman Diamond syndrome with exocrine pancreas insufficiency and skeletal dysplasia; Fanconi anemia with facial dysmorphism, squamous cell carcinomas, and liver tumors; and dyskeratosis congenita with pulmonary fibrosis, liver cirrhosis, and vascular anomalies; among others. Some disorders are associated only with myeloid malignancies (eg, *CEBPA*), whereas others confer risk to a variety of hematopoietic malignancies and solid tumors. The tumor spectrum associated with each disorder may expand over time as more individuals and families are identified. Germline predisposition alleles that confer risk to lymphoid malignancies are emerging and often overlap with the myeloid malignancy risk genes.

Because the treatment plan for many patients with AML includes allogeneic HCT and relatives are the preferred donors, testing for germline risk alleles should be performed as early as possible during clinical management. Use of hematopoietic donor stem cells from carriers of deleterious *RUNX1* and *CEBPA* variants is prohibitive, but we lack data for most predisposition genes and whether any variants are permissive to transplantation.⁶⁶ Future studies that lead to a comprehensive list of all predisposition

genes will advance our ability to provide the best treatments for patients and their families and will facilitate strategies to maintain health for them throughout their lifetimes.

Diagnostic procedures

All tests necessary to establish the diagnosis, risk classification, and the other procedures recommended to be performed at diagnosis are listed in Table 4.

Immunophenotyping

Immunophenotyping by multiparameter flow cytometry (MFC) is required to diagnose AML accurately by identifying cell surface and intracellular markers (Table 5). Because of the heterogeneity of AML, no marker is expressed in all cases. It is also important to identify leukemia-associated immunophenotypes (LAIP) for subsequent MRD monitoring by MFC. In cases where an aspirate is unobtainable and circulating blasts are absent, myeloid phenotype may be confirmed on a core biopsy using immunohistochemistry.

Cytogenetic and molecular studies

Conventional cytogenetic analysis is mandatory in the evaluation of AML. If conventional cytogenetics fails, fluorescence in situ hybridization is an alternative to detect specific abnormalities like *RUNX1::RUNX1T1*, *CBFB::MYH11*, *KMT2A (MLL)*, and *MECOM (EVI1)* gene fusions, or myelodysplasia-related chromosome abnormalities, eg, loss of chromosome 5q, 7q, or 17p material (Table 1).

Molecular genetic testing should screen for all the genetic abnormalities that define disease and risk categories or that are needed for targeted treatment modalities (Table 4). These tests can be performed by commercially available gene panel diagnostics or platforms simultaneously testing for mutations and rearrangements. When AML with germline predisposition is suspected, a dedicated gene panel including known predisposing alleles should be used. However, caution should be used in interpreting data from tumor-based panels, because hematopoietic tissues undergo somatic reversion frequently leading to false-negative results, and panel-based testing is often not able to detect germline copy number variants, which are relatively common predisposition alleles.

For patients with mutant *NPM1* and core-binding factor (CBF)-AML, it is recommended to perform baseline molecular assessment by quantitative polymerase chain reaction (qPCR) or droplet digital PCR (dPCR) to facilitate MRD monitoring after treatment.

Biobanking

At least in clinical studies, but preferably also outside this context, bone marrow and blood samples should be obtained at time of diagnosis, at remission, and at relapse and stored under appropriate conditions (DNA and RNA stored at -80°C and viable cells stored at -196°C). Broad informed consent should be obtained to allow for performance of correlative laboratory studies. In addition, a sample from healthy tissue should be stored to enable delineation of germline from somatic mutations.

Table 2. Myeloid neoplasms with germline predisposition

Syndrome name	Gene	Inheritance	Age of onset	Predisposition to other cancers	Clinical features
Myeloid neoplasms with germline predisposition without a preexisting platelet disorder or organ dysfunction					
Germline predisposition due to CEBPA P/LP variants*	CEBPA*	AD	Wide range	Not yet described	2nd allele mutations are common, typically at the 3' end Without allogeneic HCT, individuals are susceptible to additional malignancies Male mutation carriers appear to develop myeloid malignancies more often than female mutation carriers Age of onset of myeloid malignancies similar to the general population R525H hotspot occurs commonly in myeloid malignancies as a somatic mutation
Germline predisposition due to DDX41 P/LP variants	DDX41	AD	Adult > childhood	Likely	
Li-Fraumeni syndrome	TP53	AD	Wide age range	Yes	Predisposition to several tumor types
Myeloid neoplasms with germline predisposition and preexisting platelet disorders†					
Germline predisposition due to RUNX1 P/LP variants‡	RUNX1‡	AD	Wide age range	Myeloid malignancies > T-ALL > B-cell malignancies	Life-long thrombocytopenia and qualitative platelet defects
Germline predisposition due to ANKRD26 P/LP variants	ANKRD26	AD	Adult > childhood	Not yet described	Life-long thrombocytopenia, various platelet function abnormalities No syndromic features
Germline predisposition due to ETV6 P/LP variants	ETV6	AD	Wide age range	ALL > myeloid malignancies	Life-long thrombocytopenia

AA, aplastic anemia; AD, autosomal dominant; ALL, acute lymphoblastic leukemia; AR, autosomal recessive; JMML, juvenile myelomonocytic leukemia; LP, likely pathogenic; P, pathogenic.

*Approximately 10% of patients with bi-allelic CEBPA-mutant AML have one of those alleles as a germline allele, typically the 5'-end mutation, although rare 3'-end germline mutations have been described. Germline 5'-end CEBPA mutations have a penetrance of close to 100%, in contrast to germline 3'-end mutations, which have lower penetrance. Because of the high penetrance of leukemia development in those with 5'-end germline mutations, some advocate pre-emptive allogeneic HCT. Leukemia survival appears to be longer for those with a germline mutation compared with those with two acquired mutations. The presence of the acquired CEBPA mutation serves as a molecular marker of AML, and these 3'-end acquired mutations are distinct in AML that re-emerge in germline CEBPA-mutation carriers, suggesting that they are independent mutations. Therefore, individuals with germline CEBPA mutations who develop AML and are treated only with chemotherapy are at risk for developing independent AML, since their germline mutation remains. For this reason, some argue for allogeneic HCT in first remission for these patients.

†Among these, all show phenotypic variability even within the same family. People with germline ANKRD26 mutations generally have the lowest platelet counts. Germline RUNX1 mutations cause myeloid malignancies > T-cell ALL > B-cell malignancies; germline ETV6 mutations cause B-cell ALL > myeloid malignancies; and germline ANKRD26 mutations have been associated only with myeloid malignancies to date.

‡Thirty percent of germline RUNX1-mutated patients have clonal hematopoiesis prior to leukemia development, where BCOR mutations predominate. When leukemias develop, somatic mutations in the wild-type RUNX1 allele are seen commonly along with acquired mutations in ASXL1, FLT3, GATA2, PHF6, SRSF2, and WT1.

§Emerging disorders are so-named due to limited numbers of cases from the published literature at this time.

Table 2. (continued)

Syndrome name	Gene	Inheritance	Age of onset	Predisposition to other cancers	Clinical features
Myeloid neoplasms with germline predisposition and potential organ dysfunction					
Germline predisposition due to GATA2 P/LP variants	GATA2	AD	Adolescents and young adults	Yes	Associated with immunodeficiencies, lymph edema, and many other phenotypes
Severe congenital neutropenia	ELANE, G6PC3GF11, HAX1, JAGN, TCRG1, VPS45A	AD, AR	Adolescents and young adults	Not yet described	Severe opportunistic infections without growth factor support
Shwachman-Diamond syndrome	SBDS (> 90%), DNAJC21, EFL1, SRP54	AR	Childhood > adult	Not yet described	Exocrine pancreas dysfunction, variable cytopenias, skeletal dysplasia, hepatomegaly and transaminitis in early childhood, may present as nonsyndromic AA or MDS/AML
Fanconi anemia	FANCA-A-W	AR	Childhood > adult	Yes	Congenital malformations, facial dysmorphism, BM failure, squamous cell carcinomas and liver tumors, sensitivity to genotoxic agents
Telomere biology disorders/short telomere syndromes	ACD, CTC1, DKC1, MDM4, RTEL1, TERC, TERT, TINF2, ACD, NHP2, NOP10, NPM1, PARN, WRAP53, RPA1, Apollo	AD, AR, and X-linked	Wide age range	Yes	Mucocutaneous triad of nail/hair abnormalities, skin rash, leukoplakia BM failure, pulmonary fibrosis, liver cirrhosis, vascular anomalies, squamous cell carcinoma
CBL syndrome	CBL	AD	Early childhood	Not yet described	May present as nonsyndromic AA or monosomy 7 MDS
Noonan syndrome	PTPN11, NRAS, KRAS	AD	Early childhood	ALL, AML, various non-hematologic cancers	JMML/Noonan syndrome-like: facial dysmorphism, cardiac disease, musculoskeletal anomalies, cognitive deficits, vasculopathy; variable syndrome expressivity
Neurofibromatosis type I	NF1	AD	Childhood > adult	Yes	Facial dysmorphism, cardiopathy, chylothorax, hygroma, and later in life short stature
					Café au lait, neurofibromas
					Noonan syndrome-like disorder

AA, aplastic anemia; AD, autosomal dominant; ALL, acute lymphoblastic leukemia; AR, autosomal recessive; JMML, juvenile myelomonocytic leukemia; LP, likely pathogenic; P, pathogenic.

*Approximately 10% of patients with bi-allelic CEBPA-mutant AML have one of those alleles as a germline allele, typically the 5'-end mutation, although rare 3'-end germline mutations have been described. Germline 5'-end CEBPA mutations have a penetrance of close to 100%, in contrast to germline 3'-end mutations, which have lower penetrance. Because of the high penetrance of leukemia development in those with 5'-end germline mutations, some advocate pre-emptive allogeneic HCT. Leukemia survival appears to be longer for those with a germline mutation compared with those with two acquired mutations. The presence of the acquired CEBPA mutation serves as a molecular marker of AML, and these 3'-end acquired mutations are distinct in AML that re-emerge in germline CEBPA-mutation carriers, suggesting that they are independent primary AMLs rather than relapses. Therefore, individuals with germline CEBPA mutations who develop AML and are treated only with chemotherapy are at risk for developing independent AML, since their germline mutation remains. For this reason, some argue for allogeneic HCT in first remission for these patients.

†Among these, all show phenotypic variability even within the same family. People with germline ANKRD26 mutations generally have the lowest platelet counts. Germline RUNX1 mutations cause myeloid malignancies > T-cell ALL > B-cell malignancies; germline ETV6 mutations cause B-cell ALL > myeloid malignancies; and germline ANKRD26 mutations have been associated only with myeloid malignancies to date.

‡Thirty percent of germline RUNX1-mutated patients have clonal hematopoiesis prior to leukemia development, where BCOR mutations predominate. When leukemias develop, somatic mutations in the wild-type RUNX1 allele are seen commonly along with acquired mutations in ASXL1, FLT3, GATA2, PHF6, SRSF2, and WT1.

§Emerging disorders are so-named due to limited numbers of cases from the published literature at this time.

Table 2. (continued)

Syndrome name	Gene	Inheritance	Age of onset	Predisposition to other cancers	Clinical features
Germine predisposition due to <i>SAMD9</i> P/LP variants	<i>SAMD9</i>	AD	Childhood > adult	Not yet described	MIRAGE syndrome: MDS with Infections, Renal abnormalities, Adrenal Insufficiency, Genitourinary anomalies, Enteropathy May present as non-syndromic monosomy 7 MDS or BM failure
Germine predisposition due to <i>SAMD9L</i> P/LP variants	<i>SAMD9L</i>	AD	Childhood > adult	Not yet described	Ataxia-pancytopenia syndrome May present as non-syndromic monosomy 7 MDS or BM failure
Bloom syndrome	<i>BLM</i>	AR	Childhood > adult	Yes	Prenatal growth deficiency, mild immunodeficiency, excessive photosensitivity with facial lupus-like skin lesions, type 2 diabetes mellitus, hypogonadism
Germine predisposition genes causing multiple cancer types including myeloid neoplasms					
Germine predisposition due to <i>CHEK2</i> P/LP variants	<i>CHEK2</i>	AD	Adult > childhood	Yes	Predisposition to clonal hematopoiesis and several tumor types
Germine predisposition due to <i>MPL</i> P/LP variants	<i>MPL</i>	AR, AD	Adult > childhood	Also associated with lymphoid malignancies	Thrombocytopenia: AR (homozygous and compound heterozygous); thrombocytosis: AD
Germine predisposition due to <i>RECQL4</i> P/LP variants	<i>RECQL4</i>	AR	Adult > childhood	Yes	Atrophic skin and pigment changes Alopecia, osteopenia, cataracts
Hereditary breast and ovarian cancer	<i>BRCA1</i>	AD	Adult > childhood	Yes	Predisposition to several tumor types
Hereditary breast and ovarian cancer	<i>BRCA2</i>	AD	Adult > childhood	Yes	Predisposition to several tumor types
Lynch syndrome	<i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i>	AD, AR	Adult > childhood	Yes	Tumors show microsatellite instability

AA, aplastic anemia; AD, autosomal dominant; ALL, acute lymphoblastic leukemia; AR, autosomal recessive; JMML, juvenile myelomonocytic leukemia; LP, likely pathogenic; P, pathogenic.

*Approximately 10% of patients with bi-allelic *CEBPA*-mutant AML have one of those alleles as a germline allele, typically the 5'-end mutation, although rare 3'-end germline mutations have been described. Germline 5'-end *CEBPA* mutations have a penetrance of close to 100%, in contrast to germline 3'-end mutations, which have lower penetrance. Because of the high penetrance of leukemia development in those with 5'-end germline mutations, some advocate pre-emptive allogeneic HCT. Leukemia survival appears to be longer for those with a germline mutation compared with those with two acquired mutations. The presence of the acquired *CEBPA* mutation serves as a molecular marker of AML, and these 3'-end acquired mutations are distinct in AML that re-emerge in germline *CEBPA*-mutation carriers, suggesting that they are independent primary AMLs rather than relapses. Therefore, individuals with germline *CEBPA* mutations who develop AML and are treated only with chemotherapy are at risk for developing independent AML, since their germline mutation remains. For this reason, some argue for allogeneic HCT in first remission for these patients.

†Among these, all show phenotypic variability even within the same family. People with germline *ANKRD26* mutations generally have the lowest platelet counts. Germline *RUNX1* mutations cause myeloid malignancies > T-cell ALL > B-cell malignancies; germline *ETV6* mutations cause B-cell ALL > myeloid malignancies; and germline *ANKRD26* mutations have been associated only with myeloid malignancies to date.

‡Thirty percent of germline *RUNX1*-mutated patients have clonal hematopoiesis prior to leukemia development, where *BCOR* mutations predominate. When leukemias develop, somatic mutations in the wild-type *RUNX1* allele are seen commonly along with acquired mutations in *ASXL1*, *FLT3*, *GATA2*, *PHF6*, *SRSF2*, and *WT1*.

§Emerging disorders are so-named due to limited numbers of cases from the published literature at this time.

Table 2. (continued)

Syndrome name	Gene	Inheritance	Age of onset	Predisposition to other cancers	Clinical features
Nijmegen breakage syndrome	NBN	AR	Childhood > adult	Yes	>90% are homozygous for a 5-base pair deletion founder mutation Microcephaly at birth and progressive with age, dysmorphic facial features, mild growth retardation, intellectual disability, combined cellular and humoral immunodeficiency with recurrent sino-pulmonary infections, females with hypergonadotropic hypogonadism
Wiskott-Aldrich syndrome	WAS	X-linked	Adult > childhood	Yes	Immunodeficiency with microthrombocytopenia and neutropenia, eczema, recurrent infections, autoimmunity
Emerging disorders[§]					
Germine predisposition due to CSF3R P/LP variants	CSF3R	AD	Adult > childhood	Not yet described	Full syndrome description awaits publication of additional cases
Germine predisposition due to ERCC6L2 P/LP variants	ERCC6L2	AR (homozygous)	Adult > childhood	Not yet described	Full syndrome description awaits publication of additional cases
Germine predisposition due to JAK2 P/LP variants	JAK2	AD	Adult > childhood	Not yet described	Associated with thrombocytopenia
Germine predisposition due to MBD4 P/LP variants	MBD4	AD	Adult > childhood	Likely	Myeloid malignancies have a high mutational rate Somatic mutation of DNMT3A is common

AA, aplastic anemia; AD, autosomal dominant; ALL, acute lymphoblastic leukemia; AR, autosomal recessive; JMML, juvenile myelomonocytic leukemia; LP, likely pathogenic; P, pathogenic.

*Approximately 10% of patients with bi-allelic CEBPA-mutant AML have one of those alleles as a germline allele, typically the 5'-end mutation, although rare 3'-end germline mutations have been described. Germline 5'-end CEBPA mutations have a penetrance of close to 100%, in contrast to germline 3'-end mutations, which have lower penetrance. Because of the high penetrance of leukemia development in those with 5'-end germline mutations, some advocate pre-emptive allogeneic HCT. Leukemia survival appears to be longer for those with a germline mutation compared with those with two acquired mutations. The presence of the acquired CEBPA mutation serves as a molecular marker of AML, and these 3'-end acquired mutations are distinct in AML that re-emerge in germline CEBPA-mutation carriers, suggesting that they are independent primary AMLs rather than relapses. Therefore, individuals with germline CEBPA mutations who develop AML and are treated only with chemotherapy are at risk for developing independent AML, since their germline mutation remains. For this reason, some argue for allogeneic HCT in first remission for these patients.

†Among these, all show phenotypic variability even within the same family. People with germline ANKRD26 mutations generally have the lowest platelet counts. Germline RUNX1 mutations cause myeloid malignancies > T-cell ALL > B-cell malignancies; germline ETV6 mutations cause B-cell ALL > myeloid malignancies; and germline ANKRD26 mutations have been associated only with myeloid malignancies to date.

‡Thirty percent of germline RUNX1-mutated patients have clonal hematopoiesis prior to leukemia development, where BCOR mutations predominate. When leukemias develop, somatic mutations in the wild-type RUNX1 allele are seen commonly along with acquired mutations in ASXL1, FLT3, GATA2, PHF6, SRSF2, and WT1.

§Emerging disorders are so-named due to limited numbers of cases from the published literature at this time.

Table 2. (continued)

Syndrome name	Gene	Inheritance	Age of onset	Predisposition to other cancers	Clinical features
Germine predisposition due to <i>MECOM/EVI1</i> P/LP variants	<i>MECOM/EVI1</i>	AD	Childhood > adult	Not yet described	Radioulnar synostosis, clinodactyly, cardiac and renal malformations, presenile hearing loss BM failure, B-cell deficiency
Germine predisposition due to <i>NPM1</i> P/LP variants	<i>NPM1</i>	AD	Childhood > adult	Not yet described	Full syndrome description awaits publication of additional cases
Germine predisposition due to <i>RBBP6</i> P/LP variants	<i>RBBP6</i>	AD	Adult > childhood	Not yet described	Full syndrome description awaits publication of additional cases
Germine predisposition due to <i>SRP72</i> P/LP variants	<i>SRP72</i>	AD	Wide age range	Not yet described	Full syndrome description awaits publication of additional cases
Germine predisposition due to <i>TET2</i> P/LP variants	<i>TET2</i>	AD, AR	Childhood > adult	Not yet described	Full syndrome description awaits publication of additional cases

AA, aplastic anemia; AD, autosomal dominant; ALL, acute lymphoblastic leukemia; AR, autosomal recessive; JMML, juvenile myelomonocytic leukemia; LP, likely pathogenic; P, pathogenic.

*Approximately 10% of patients with bi-allelic *CEBPA*-mutant AML have one of those alleles as a germline allele, typically the 5'-end mutation, although rare 3'-end germline mutations have been described. Germline 5'-end *CEBPA* mutations have a penetrance of close to 100% in contrast to germline 3'-end mutations, which have lower penetrance. Because of the high penetrance of leukemia development in those with 5'-end germline mutations, some advocate pre-emptive allogeneic HCT. Leukemia survival appears to be longer for those with a germline mutation compared with those with two acquired mutations. The presence of the acquired *CEBPA* mutation serves as a molecular marker of AML, and these 3'-end acquired mutations are distinct in AML that re-emerge in germline *CEBPA*-mutation carriers, suggesting that they are independent primary AMLs rather than relapses. Therefore, individuals with germline *CEBPA* mutations who develop AML and are treated only with chemotherapy are at risk for developing independent AML, since their germline mutation remains. For this reason, some argue for allogeneic HCT in first remission for these patients.

†Among these, all show phenotypic variability even within the same family. People with germline *ANKRD26* mutations generally have the lowest platelet counts. Germline *RUNX1* mutations cause myeloid malignancies > T-cell ALL > B-cell malignancies; germline *ETV6* mutations cause B-cell ALL > myeloid malignancies; and germline *ANKRD26* mutations have been associated only with myeloid malignancies to date.

‡Thirty percent of germline *RUNX1*-mutated patients have clonal hematopoiesis prior to leukemia development, where *BCOR* mutations predominate. When leukemias develop, somatic mutations in the wild-type *RUNX1* allele are seen commonly along with acquired mutations in *ASXL1*, *FLT3*, *GATA2*, *PHF6*, *SRSF2*, and *WT1*.

§Emerging disorders are so-named due to limited numbers of cases from the published literature at this time.

Table 3. Clinical features prompting consideration of clinical testing for a germline predisposition allele(s)

Clinical features
Personal history of ≥ 2 cancers, 1 of which is a hematopoietic malignancy (order does not matter)
Personal history of a hematopoietic malignancy plus: <ul style="list-style-type: none"> • Another relative within two generations with another hematopoietic malignancy, or • Another relative within two generations with a solid tumor diagnosed at age 50 or younger, or • Another relative within two generations with other hematopoietic abnormalities
Presence of a deleterious gene variant in tumor profiling that could be a germline allele, especially if that variant is present during remission*
Age of diagnosis of hematopoietic malignancy at an earlier age than average (eg, MDS diagnosed ≤ 40 y)
Germline status of a variant is confirmed by: <ul style="list-style-type: none"> Its presence in DNA derived from a tissue source not likely to undergo somatic mutation frequently (eg, cultured skin fibroblasts or hair follicles) AND at a variant allele frequency consistent with the germline (generally considered between 30-60%), or Its presence in at least two relatives at a variant allele frequency consistent with the germline

*Certain gene alleles (eg, *CHEK2* I200T and truncating *DDX41* variants) are overwhelmingly likely to be germline and should prompt consideration of germline testing when identified even once.

2022 European LeukemiaNet genetic risk classification at diagnosis

Since 2017, new data have emerged that prompted the need to adjust the risk classification. In addition to baseline genetic characterization, the importance of response to initial therapy and assessment of early MRD in individual risk assignment are highlighted.⁶⁷ In clinical practice, a patient with favorable-risk AML may be reclassified as intermediate-risk or vice versa, based on the presence or absence of MRD, respectively. For instance, this is particularly relevant for patients with *NPM1*-mutant AML.⁶⁸⁻⁷⁰

The most important changes made to the previous risk classification are outlined in Table 6. (1) The *FLT3*-ITD allelic ratio is no longer considered in the risk classification; consequently, AML with *FLT3*-ITD (without adverse-risk genetic lesions) are now categorized in the intermediate-risk group, irrespective of the allelic ratio or concurrent presence of *NPM1* mutation. The reason for this change relates to methodological issues with standardizing the assay to measure the *FLT3*-ITD allelic ratio, the modifying impact of midostaurin-based therapy on *FLT3*-ITD without *NPM1* mutation,⁷¹ and the increasing role of MRD in treatment decisions. (2) AML with myelodysplasia-related gene mutations is now categorized in the adverse-risk group. These mutations, typically associated with AML following an antecedent hematologic disease, are also prevalent in de novo AML and indicate adverse risk even in the absence of myelodysplasia-related cytogenetic abnormalities.^{6,26,42,44,45} Beyond the previously considered *ASXL1* and/or *RUNX1* genes, this category of myelodysplasia-related gene mutations now includes pathologic variants in at least one of the *ASXL1*, *BCOR*, *EZH2*, *RUNX1*, *SF3B1*, *SRSF2*, *STAG2*, *U2AF1*, or *ZRSR2* genes. (3) The presence of adverse-risk cytogenetic abnormalities in *NPM1*-mutated AML now defines adverse risk. A meta-analysis has shown that *NPM1*-mutated AML with adverse cytogenetic abnormalities is associated with a poor outcome.⁷² Whether other genetic abnormalities (eg, myelodysplasia-related gene mutations) also confer unfavorable outcome to *NPM1*-mutated AML is under investigation. (4) As mentioned previously, recent studies have

shown that in-frame mutations affecting the basic leucine zipper region of *CEBPA* confer the favorable outcome, irrespective of their occurrence as biallelic or monoallelic mutations and therefore are now categorized in the favorable-risk group.^{32,34,35} (5) Additional disease-defining recurring cytogenetic abnormalities are included in the adverse-risk group, including t(3q26.2;v) involving the *MECOM* gene,^{31,73} or t(8;16)(p11.2;p13.3) associated with *KAT6A::CREBBP* gene fusion.¹⁴ (6) Finally, hyperdiploid karyotypes with multiple trisomies (or polysomies) are no longer considered complex karyotypes and as adverse risk.⁷⁴

Although numerous reports have studied mutations in other genes, for example, *IDH1/IDH2* or *DNMT3A*, current evidence does not yet warrant their assignment to a distinct ELN prognostic group. Also, the emerging therapeutic use of targeted inhibitors might impact prognostic outcome in *IDH1/IDH2*-mutated AML. Finally, it should be emphasized that the ELN AML risk classification has been developed based on data from intensively treated patients and may warrant modifications for patients receiving less intensive therapies.

Monitoring of measurable residual disease

MRD assessment in AML is used to (1) provide a quantitative methodology to establish a deeper remission status; (2) refine postremission relapse risk assessment; (3) identify impending relapse to enable early intervention; and (4) as a surrogate end point to accelerate drug testing and approval.⁷⁵

Currently, the 2 most extensively evaluated methodologies are multiparameter flow cytometry-based MRD (MFC-MRD) and molecular MRD (Mol-MRD) assessed by qPCR.⁷⁶ Emerging exploratory technologies are next-generation sequencing (NGS) and dPCR (Table 7).⁷⁷ The current update of the ELN recommendation on MRD includes new technical recommendations for standardized MFC-MRD and Mol-MRD analysis, MRD

Table 4. Tests and procedures at diagnosis for a patient with AML

Tests and procedures		
Tests to establish the diagnosis Complete blood count and differential count* Bone marrow aspirate† Bone marrow trephine biopsy‡ Immunophenotyping by flow cytometry (see Table 5)		Additional tests and procedures Complete physical examination ^c Performance status (ECOG/WHO score) Geriatric assessment ^d (optional) Biochemistry, coagulation tests ^e Hepatitis A, B, C; HIV-1 testing; CMV, EBV, HSV, VZV Serum pregnancy test ^f Eligibility assessment for allogeneic HCT (incl. HLA-typing) ^g Chest x-ray, 12-lead electrocardiogram, echocardiography or MUGA (on indication) Computed tomography of the chest (on indication) ^h Lumbar puncture (on indication) ⁱ Information on oocyte and sperm cryopreservation ^j Biobanking ^k
Genetic analyses Cytogenetics§ Screening for gene mutations required for establishing the diagnosis and to identify actionable therapeutic targets# <ul style="list-style-type: none">• <i>FLT3</i>,¶ <i>IDH1</i>, <i>IDH2</i>• <i>NPM1</i>• <i>CEBPA</i>,# <i>DDX41</i>, <i>TP53</i>; <i>ASXL1</i>, <i>BCOR</i>, <i>EZH2</i>, <i>RUNX1</i>, <i>SF3B1</i>, <i>SRSF2</i>, <i>STAG2</i>, <i>U2AF1</i>, <i>ZRSR2</i> Screening for gene rearrangements** <ul style="list-style-type: none">• <i>PML::RARA</i>, <i>CBFB::MYH11</i>, <i>RUNX1::RUNX1T1</i>, <i>KMT2A</i> rearrangements, <i>BCR::ABL1</i>, other fusion genes (if available)	Results preferably available within <ul style="list-style-type: none">• 5-7 d <	

CMV, cytomegalovirus; EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; HSV, herpes simplex virus; MUGA, multigated acquisition; VZV, varicella-zoster virus.

*Two hundred nucleated cells on blood smears should be counted.

†Five hundred nucleated cells on bone marrow smears should be counted. Myeloblasts, monoblasts, and megakaryoblasts are included in the blast count. Monoblasts and promonocytes, but not abnormal monocytes, are counted as blast equivalents in AML with monocytic or myelomonocytic differentiation.

‡In patients with a dry tap (*punctio sicca*); touch preparations from the core biopsy should be performed if a dry tap is suspected.

§At least 20 bone marrow metaphases are needed to define a normal karyotype and recommended to describe an abnormal karyotype. Normal and abnormal karyotypes may be diagnosed from blood specimens with circulating blasts. In case of no analyzable metaphases, fluorescence in-situ hybridization is an alternative method to detect genetic abnormalities like *RUNX1::RUNX1T1*, *CBFB::MYH11*, *KMT2A*, and *MECOM* gene fusions, or myelodysplasia-related chromosome abnormalities, eg, loss of chromosome 5q, 7q, or 17p material.

#Screening for gene mutations is an evolving field of research; screening for single genes is increasingly replaced by gene panel diagnostics.

¶*FLT3*: mutational screening should include the analysis of internal tandem duplications (ITD) and of tyrosine kinase domain (TKD) mutations. Longer *FLT3*-ITDs may be missed by next-generation sequencing, therefore, we recommend continuing to use capillary electrophoresis.

#The report should specify type of mutation: only in-frame mutations affecting the basic leucine zipper (bZIP) region of *CEBPA*, irrespective whether they occur as monoallelic or biallelic mutations, have been associated with favorable outcome.

**Screening for gene rearrangements should be performed if rapid information is needed for recommendation of suitable therapy, if chromosome morphology is of poor quality, or if there is typical morphology but the suspected cytogenetic abnormality is not present.

††Results from these genes are not required for establishing the diagnosis or for the identification of actionable therapeutic targets, rather they may be used for subsequent monitoring of the disease by next-generation sequencing-based techniques (with the exception of mutations consistent with pre-malignant clonal hematopoiesis, eg, *DNMT3A*, *TET2*, *ASXL1*); although these techniques are still investigational, this is a rapidly evolving field.

‡‡Including race or ethnicity, prior exposure to toxic agents, prior malignancy, therapy for prior malignancy, information on smoking.

^aThorough family history needed to identify potential myeloid neoplasms with germline predisposition.

^bHistory of bleeding episodes may inform cases of myeloid neoplasms with germline predisposition and preexisting platelet disorders.

^cSpecial attention for skin (bleeding symptoms, leukemia cutis, Sweet syndrome), gingival hyperplasia, lymphadenopathy, testis enlargement, signs of infection (eg, pulmonary, perianal, mouth/teeth); symptoms of central nervous system involvement; signs of abnormalities associated with germline predisposition syndromes (Table 2).

^dTests for objectively measured physical and cognitive function are particularly useful in the context of trials.

^eBiochemistry: glucose, sodium, potassium, calcium, creatinine, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, lactate dehydrogenase (LDH), bilirubin, urea, total protein, uric acid, total cholesterol, total triglycerides, creatinine phosphokinase (CPK). Special attention should be given to tumor lysis syndrome. Coagulation tests: prothrombin time (PTT), international normalized ratio (INR) where indicated, activated partial thromboplastin time (aPTT).

^fIn women with childbearing potential.

⁹HLA typing and CMV testing should be performed in those patients eligible for allogeneic HCT. In patients in whom allogeneic HCT is likely to be indicated, it is also important to commence a search for sibling or volunteer unrelated donor at diagnosis.

¹⁰If suspicion of pulmonary infection.

¹¹Required in patients with clinical symptoms suspicious of central nervous system involvement; patient should be evaluated by imaging study for intracranial bleeding, leptomeningeal disease, and mass lesion; lumbar puncture considered optional in other settings (eg, high white blood cell count).

¹²Cryopreservation to be done in accordance with the wish of the patient.

¹³Pretreatment leukemic bone marrow and blood sample; preferably also normal tissue (eg, skin biopsy, nail clippings).

thresholds, definitions of MRD response, and suggestions for clinical implications.⁶⁷

Multiparameter flow cytometry

Integration of diagnostic LAIP that distinguish AML cells from normal hematopoietic cells in an individual patient and the more generally defined “different from normal” aberrant immunophenotype (DfN) allow both for tracking of diagnostic and emerging clones and should include core MRD markers (Table 5).⁶⁷ MFC-MRD assessment should be performed with a qualified assay based on guidelines for rare event detection.⁷⁸ Evaluation of residual leukemic stem cells (LSC) by MFC-MRD is still investigational but is recommended for evaluation in clinical studies. The prognostic value of LSC-MRD has been associated with a higher sensitivity and lower false negativity.^{79,80} LSC can be immunophenotypically defined as CD34⁺/CD38^{low} cells combined with an aberrant marker not present on normal HSCs (eg, CD45RA [PTPRC], CLL-1 [CLEC12A], or CD123 [IL3RA]).⁸¹

Molecular MRD

The technique used, including qPCR and dPCR, should reach a limit of detection of at least 10⁻³. Either peripheral blood or bone marrow may be used, although sensitivity in blood is generally lower by an order of magnitude compared with bone marrow. Leukemia-related abnormalities suitable for qPCR monitoring include mutated *NPM1*; *CBFB::MYH11*, *RUNX1::RUNX1T1*, *KMT2A::MLLT3*, *DEK::NUP214*, and *BCR::ABL1* gene fusions; and *WT1* expression.⁶⁷ Validation is most robust for *NPM1*-mutated, as well as *CBFB::MYH11* and *RUNX1::RUNX1T1*-positive AML.⁸²

If using NGS, error-corrected targeted panel-based approaches are preferred.⁸³ Care must be taken to recognize and exclude germline mutations. Mutations consistent with premalignant clonal hematopoiesis (eg, *DNMT3A*, *TET2*, *ASXL1*) should not be considered as MRD.⁸⁴ Further study is required to identify and distinguish mutations truly indicative of residual AML from clonal hematopoiesis related abnormalities.^{85,86} It is important to note that NGS-based strategies currently lack standardization as a stand-alone technique for MRD assessment.

Implementation of MRD testing/decision making in AML

The prognostic value of MRD detection in complete remission (CR) or CR with incomplete hematologic recovery (CRI) has been demonstrated both in patients treated with intensive and more recently less-intensive treatment modalities.⁸⁷⁻⁸⁹ Various studies and a systematic meta-analysis of 81 publications have shown the prognostic value of MRD for relapse and overall survival (OS).^{68,87,90-93} Although MRD estimates furnish critical prognostic insights, they are imperfect, because relapse still occurs in a minority of MRD-negative patients. Thus, a negative MRD test result may not indicate complete disease eradication but refers

to disease below the MRD test threshold in the tested sample. Conversely, not all patients who are MRD positive will relapse. Of note, Mol-MRD may remain detectable at low levels (CR_{MRD-L}) without prognostic significance, and therefore, are called negative operationally if the MRD values are below the threshold linked to prognosis.⁶⁷ For instance, in CBF-AML and *NPM1*-mutant AML, the transcripts may show persistent low-level expression after treatment, but this is not prognostic of relapse.^{68,70,94-96} The presence of detectable MRD before transplant is an independent unfavorable predictor of posttransplant outcome.⁹⁷⁻¹⁰⁰ However, there is currently no evidence showing benefit of additional courses of intensive chemotherapy prior to transplant in CR1 patients who are MRD positive. If fit enough, such patients should be considered candidates for a myeloablative conditioning (MAC) regimen or an early taper of posttransplant immunosuppression.⁹⁸

Definitions of MRD response categories and molecular relapse are listed in Table 8. In Figure 2, the recommended time points for MRD evaluation and clinical decision making are depicted for *NPM1*-mutated, CBF-AML, and AML assessed by MFC.

Response criteria and outcome measures

AML response criteria and outcome measures are summarized in Tables 8 and 9.

Response criteria

CR, CRI, partial remission (PR), and morphologic leukemia-free state (MLFS) The criterion “absence of blasts with Auer rods” was eliminated.

CR with partial hematologic recovery The term CR with partial hematologic recovery (CRh) has been introduced for patients with morphologic bone marrow blast clearance and partial recovery of both neutrophils ($\geq 0.5 \times 10^9/L$ [500/ μL]) and platelets ($\geq 50 \times 10^9/L$ [50 000/ μL]) because those represent clinical benefit to the patient; other CR criteria need to be met. Thus far, CRh has only been used in the context of trials evaluating less-intensive therapies. It is recommended that future studies validate the role of CRh as a surrogate measure of survival after intensive and less-intensive therapies.

Response criteria with MRD assessment The 2017 ELN recommendations included the term CR without MRD (CR_{MRD-}) to recognize the increasing role of MRD technologies in stratifying prognosis of patients in CR.¹ The current response criteria expand MRD classification to include patients achieving CRh or CRI without MRD (CR_{hMRD-} or CRI_{MRD-}).

Table 5. Expression of cell-surface and cytoplasmic markers for the diagnosis of AML and MPAL

Diagnosis of AML	
Diagnosis of AML	
Precursor marker	CD34, CD117, HLA-DR
Myeloid markers	Cytoplasmic MPO, CD33, CD13
Myeloid maturation markers	CD11b, CD15, CD64, CD65
Monocytic markers	CD14, CD36, CD64, CD4, CD38, CD11c
Megakaryocytic markers	CD41 (glycoprotein IIb/IIIa), CD61 (glycoprotein IIIa), CD36
Erythroid markers	CD235a (glycophorin A), CD71, CD36
Diagnosis of MPAL	
Myeloid lineage	MPO (flow cytometry, immunohistochemistry or cytochemistry), or monocytic differentiation (at least 2 of the following: non-specific esterase cytochemistry, CD11c, CD14, CD64, lysozyme), or at least two myeloid markers, ie, CD177, CD33, CD13
T-lineage	Strong cytoplasmic CD3 (with antibodies to CD3 ϵ chain) or surface CD3
B-lineage ^a	Strong CD19 with at least one of the following strongly expressed: cytoplasmic CD79a, cCD22 or CD10, or weak CD19 with at least two of the following strongly expressed: CD79a, cCD22 or CD10
Core MRD markers	CD34, CD117, CD45, CD33, CD13, CD56, CD7, HLA-DR If monocytic: CD64, CD11b, CD4 (in addition)

Time window for response assessment To recognize the potential for continuing improvements in blood counts after myelosuppressive therapy, response definitions for patients with marrow blast clearance (<5%) may be adjusted to reflect the best hematologic response achieved prior to commencement of the next treatment cycle. Aspirate reports that include MLFS, CRh, or CRi should note the potential for post-marrow blood counts to alter the final response designation.

No response Patients evaluable for response but not meeting the criteria for CR, CRh, CRi, MLFS, or PR will be categorized as having “no response.”

Nonevaluable for response For accurate reporting of response, it is necessary to include all registered/randomized patients on an intention to treat principle. Therefore, patients nonevaluable for response should be included in the denominator of response assessment analyses. This category may include

patients yet to have a response assessment, suffering early death, exiting the study early, or those with a technically sub-optimal bone marrow sample precluding assessment. Patients previously categorized as having death in aplasia or from indeterminate causes are now designated as nonevaluable for response.

Treatment failure

Relapsed disease is defined as $\geq 5\%$ leukemic blasts in the bone marrow, reappearance of leukemic blasts in peripheral blood (PB) in at least 2 PB samples at least 1 week apart, or development of new extramedullary disease.

Refractory disease If a specified response has not been achieved by a defined landmark (ie, failure to achieve response after 2 cycles of intensive chemotherapy or a predetermined landmark, eg, 180 days after commencing less-intensive therapy), the patient will be designated as having *refractory disease*.

CR, CRh, or CRi with MRD relapse For patients initially achieving CR, CRh, or CRi without MRD, the term CR, CRh, or CRi with MRD relapse may be applied if there is evidence of MRD relapse as defined by ELN criteria (Table 8).⁶⁷

Outcome measures

Systematic reporting of early death (eg, 30 and 60 days) is recommended to enable assessment of treatment-related mortality with new therapies being relevant for the therapy under consideration.

Although the primary end point for registrational studies in AML has historically been OS, the increased availability of post-study treatment options with potential to confound OS interpretation may encourage adoption of alternative end points, such as event-free survival (EFS; or relapse-free survival [RFS] for postremission studies) as comparative outcome measures in registrational studies (see also “Clinical trials”). In a retrospective patient-level analysis of 8 randomized trials evaluating intensive chemotherapy conducted by the US Food and Drug Administration (FDA), EFS had the best correlation with OS when response was limited to a strict CR ($R^2 = 0.87$; 95% confidence interval [CI], 0.47-0.98); EFS with the definition of response broadened to include CRi and CR with incomplete platelet recovery was also shown to correlate, albeit less strongly, with OS ($R^2 = 0.59$; 95% CI, 0.13-0.93).¹⁰¹ Limitations of the analysis included relatively small sample sizes, heterogeneity among trials, and lack of multivariate analyses.

For drugs that add myelosuppression (eg, venetoclax, CPX-351, gemtuzumab ozogamycin), the sole use of a strict CR in the definition of EFS is increasingly challenged. We recommend broadening the definition of EFS to include CRh or CRi in response. Patients not achieving response by the predetermined landmark (refractory disease) should have the event recorded on day 1 of registration in nonrandomized trials (or day 1 of random assignment in randomized trials). Patients who die before reaching the response landmark and prior to/without response assessments are considered treatment failures and should have the event recorded at day 1 of registration/randomization. Patients alive but nonevaluable for response are censored at day 1 of registration/randomization. To enable consistency in trial reporting, a response landmark for failure to achieve response should be

Table 6. 2022 ELN risk classification by genetics at initial diagnosis*

Risk category†	Genetic abnormality
Favorable	<ul style="list-style-type: none"> t(8;21)(q22;q22.1)/RUNX1::RUNX1T1†,‡ inv(16)(p13.1;q22) or t(16;16)(p13.1;q22)/CBFB::MYH11†,‡ Mutated NPM1†,§ without FLT3-ITD bZIP in-frame mutated CEBPA
Intermediate	<ul style="list-style-type: none"> Mutated NPM1†,§ with FLT3-ITD Wild-type NPM1 with FLT3-ITD (without adverse-risk genetic lesions) t(9;11)(p21.3;q23.3)/MLLT3::KMT2A†,¶ Cytogenetic and/or molecular abnormalities not classified as favorable or adverse
Adverse	<ul style="list-style-type: none"> t(6;9)(p23.3;q34.1)/DEK::NUP214 t(v;11q23.3)/KMT2A-rearranged# t(9;22)(q34.1;q11.2)/BCR::ABL1 t(8;16)(p11.2;p13.3)/KAT6A::CREBBP inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1) t(3q26.2;v)/MECOM(EVI1)-rearranged −5 or del(5q); −7; −17/abn(17p) Complex karyotype,** monosomal karyotype†† Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2‡‡ Mutated TP53^a

*Frequencies, response rates and outcome measures should be reported by risk category, and, if sufficient numbers are available, by specific genetic lesions indicated.

†Mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease.

‡Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization.

§AML with NPM1 mutation and adverse-risk cytogenetic abnormalities are categorized as adverse-risk.

||Only in-frame mutations affecting the basic leucine zipper (bZIP) region of CEBPA, irrespective whether they occur as monoallelic or biallelic mutations, have been associated with favorable outcome.

¶The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations.

#Excluding KMT2A partial tandem duplication (PTD).

**Complex karyotype: ≥3 unrelated chromosome abnormalities in the absence of other class-defining recurring genetic abnormalities; excludes hyperdiploid karyotypes with three or more trisomies (or polysomies) without structural abnormalities.

††Monosomal karyotype: presence of two or more distinct monosomies (excluding loss of X or Y), or one single autosomal monosomy in combination with at least one structural chromosome abnormality (excluding core-binding factor AML).

‡‡For the time being, these markers should not be used as an adverse prognostic marker if they co-occur with favorable-risk AML subtypes.

^aTP53 mutation at a variant allele fraction of at least 10%, irrespective of the TP53 allelic status (mono- or biallelic mutation); TP53 mutations are significantly associated with AML with complex and monosomal karyotype.

prespecified. Furthermore, the response landmark should be relevant for the treatment received; for example, after completion of 2 cycles of intensive therapy or 180 days after commencing less-intensive approaches.

The incorporation of MRD outcomes as a measure of treatment failure necessitates the inclusion of new terms incorporating molecular MRD relapse into time to event definitions for EFS_{MRD}, RFS_{MRD}, and cumulative incidence of relapse (CIR_{MRD}; Table 9). For each study, clear definitions regarding how MRD relapse is determined should be specified in the statistical analysis plan.

Therapy for AML

The goal of treatment is control and, whenever possible, eradication of disease. This outcome is accomplished ideally by inducing a CR with initial therapy, followed by consolidation and/or maintenance efforts to deepen the remission and maximize response duration. The role of HCT and post-HCT therapies is discussed in the section on allogeneic HCT. Results of genetic analyses should be available as rapidly as possible, preferably within 3 to 5 days, to identify therapeutically actionable targets (Table 4). A short delay in starting treatment to stabilize patients and identify the best treatment option is recommended to optimize clinical outcome.¹⁰² If hyperleukocytosis is present, immediate cytoreduction is advised (see Management of special situations). If a patient cannot tolerate an active intensive or nonintensive treatment option, the purpose of therapy is to optimize quality of life and decrease the incidence of cytopenia-related complications with transfusion and other supportive care measures and early involvement of palliative care services as appropriate.

The survival of patients with AML that are related to previous therapy overall remains poor, which is mainly due to the high frequency of adverse (cyto)genetic features,^{103,104} but also to the sequelae of prior therapy and sometimes persistent primary disease. In general, patients should be managed according to the same general therapeutic principles depending on whether they are candidates for intensive or nonintensive therapy and allogeneic HCT.^{104,105} CPX-351 offers a new option for the treatment of these patients (see below).

Patients considered fit for intensive therapy

Induction therapy Anthracyclines and cytarabine remain the backbone of intensive chemotherapy. Alternative options are fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) and mitoxantrone-based cytarabine regimens (Table 10). It has become standard to incorporate the kinase inhibitor midostaurin into first-line therapy for patients with FLT3-mutant AML. Midostaurin improved 4-year OS by 7.1%, from 44.3 to 51.4% when used as an adjunct to daunorubicin-cytarabine induction and high-dose cytarabine consolidation in patients 18 to 59 years of age.¹⁰⁶ Although study treatment incorporated single-agent maintenance for 12 monthly cycles, the value of adding maintenance therapy remains uncertain.¹⁰⁷ In a prospective nonrandomized study, midostaurin also showed a beneficial effect in patients up to 70 years of age in comparison with a historical control group.¹⁰⁸

Newer and potentially more potent FLT3 inhibitors are currently under randomized evaluation as therapeutic alternatives to midostaurin.^{109,110} A placebo-controlled phase 3 trial enrolled 539 patients to either quizartinib or placebo in combination with intensive induction and consolidation chemotherapy followed by single agent quizartinib maintenance for up to 36 cycles in patients 18 to 75 years of age with FLT3-ITD-positive AML. Post-HCT maintenance was permitted. Although peer-reviewed results are not yet available, a preliminary meeting abstract reported prolonged OS for quizartinib compared with placebo. Grade ≥3 treatment-emergent neutropenia was more frequent in the quizartinib arm; early death (≤30 days) was 5.7% and 3.1% in the quizartinib compared with placebo arms, respectively.¹¹¹

Table 7. Methods for detection of MRD in AML

	Method	Target	Sensitivity	Applicable in % of AML	Turn-around time (days)	Limitations/problems
Established	Multi-parameter flow cytometry (MFC)	Leukemia-associated immunophenotype (LAIP) or different from normal (DfN)	10^{-3} to 10^{-4}	85-90	2	Less sensitive, more subjective analysis
Established	Real-time quantitative PCR (RT-qPCR)	Robust data: <i>NPM1</i> , <i>CBFB::MYH11</i> , <i>RUNX1::RUNX1T1</i> Less validated: <i>KMT2A::MLL73</i> , <i>DEK::NUP214</i> , <i>BCR::ABL1</i> , <i>WT1</i>	10^{-4} to 10^{-5}	40-50*	3-5	Limited applicability
Exploratory	Next-generation sequencing (NGS)†,‡	Potentially any somatic mutation†	10^{-2} to 10^{-4}	~100	5-10	Less sensitive, costly, technically challenging
Exploratory	Digital PCR (dPCR)	Specific targeted mutations	10^{-3} to 10^{-4}	~70	3-5	Specific assay necessary for every mutation, limited sensitivity

*Less frequent in elderly patients with AML.

†The NGS-MRD threshold has not been defined for individual mutations; NGS-MRD positivity is provisionally defined as $\geq 0.1\%$ variant allele frequency, excluding mutations related to clonal hematopoiesis and germline mutations.

‡Common gene mutations consistent with pre-malignant clonal hematopoiesis such as *DNMT3A*, *TET2*, and *AXSL1* excluded; further study is required to determine which mutations are truly indicative of residual AML and not clonal hematopoiesis.

Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 IgG4 antibody chemically linked to a calicheamicin-based cytotoxic warhead. Following a history of initial FDA approval followed by retraction based on questionable clinical benefit, a subsequent randomized study demonstrated an EFS advantage among patients 50 to 70 years with de novo AML, with benefit limited to favorable or intermediate cytogenetic risk disease.^{112,113} Although 4 other open-label randomized studies individually failed to demonstrate improved survival for GO added to front line therapy in AML, a meta-analysis of all 5 studies indicated a benefit, particularly in patients with CBF-AML.¹¹⁴ In another randomized study, a reduction of the relapse probability and greater mutant *NPM1* molecular clearance was shown in patients with *NPM1*-mutated AML, but with no EFS difference.^{70,115} GO dosed at 3 mg/m² (capped at 5 mg) D1, 4, and 7 of induction and day 1 of consolidation has been approved for patients with previously untreated CD33 antigen positive AML in combination with daunorubicin and cytarabine, but a single dose of GO delivered on day 1 of induction may also be efficacious.^{114,116,117}

CPX-351 is a dual-drug liposomal formulation that encapsulates cytarabine/daunorubicin in a 5:1 fixed molar ratio.¹¹⁸ In an open label phase 3 randomized study in newly diagnosed patients aged 60 to 75 years with disease subtypes including therapy-related AML, a history of MDS or CMML, or de novo AML with myelodysplasia-related cytogenetic abnormalities CPX-351 improved the clinical response rate and OS compared with induction with cytarabine-daunorubicin, followed by "5 + 2" consolidation.¹¹⁹ Five-year OS in the CPX-351 arm was improved from 10% to 18% compared with patients receiving "7 + 3."¹²⁰ CPX-351 delayed the median time to neutrophil and platelet recovery

by approximately 7 days and increased the risk of bleeding. Early 30-day mortality, however, was not increased by CPX-351 (5.9%) compared with "7 + 3" (10.6%), and less mucositis was noted. Randomized data are lacking for patients under 60 years and for AML following prior MPN.

Consolidation therapy After attainment of CR (or CRh/CRi), patients are consolidated ideally with regimens that include intermediate-dose cytarabine.¹²¹ Consecutive administration on days 1 to 3, rather than on alternate days (days 1, 3, and 5) may hasten blood count recovery.^{122,123} Although high-dose cytarabine (3000 mg/m²) is still used in some centers, its greater toxicity and failure to improve survival argues against its continued use.¹²⁴⁻¹²⁶

In addition to baseline risk factors, assessment of MRD in CR (or CRh/CRi) is recommended for patients with nonadverse risk in first remission to inform consolidation treatment choice. For patients with an estimated relapse risk exceeding 35% to 40%, consolidation with allogeneic HCT remains the preferred postremission option.¹²⁷ These include patients with adverse-risk AML or nonadverse-risk disease with MRD persistence. Autologous HCT, although not widely used, offers an alternative postremission option for patients with favorable- or intermediate-risk disease with an adequate MRD response or for whom allogeneic HCT is not available.¹²⁸ In the subset of patients receiving induction with a FLT3 inhibitor, GO or CPX-351, these agents may be incorporated into consolidation (Table 10).

Maintenance therapy There is no generally accepted definition of "maintenance therapy." In most previous trials, maintenance therapy has been administered for a defined period of time in patients who achieved remission after intensive

Table 8. Response criteria in AML

Category	Definition	Comment
Response		
CR*,†,‡	Bone marrow blasts < 5%; absence of circulating blasts; absence of extramedullary disease; ANC $\geq 1.0 \times 10^9/L$ (1,000/ μL); platelet count $\geq 100 \times 10^9/L$ (100 000/ μL)	
CRh*,†,‡	ANC $\geq 0.5 \times 10^9/L$ (500/ μL) and platelet count $\geq 50 \times 10^9/L$ (50 000/ μL), otherwise all other CR criteria met	If CRh used, CRi should only include patients not meeting the definition of CRh
CRi*,†,‡	All CR criteria except for residual neutropenia < $1.0 \times 10^9/L$ (1,000/ μL) or thrombocytopenia < $100 \times 10^9/L$ (100 000/ μL)	
MLFS	Bone marrow blasts < 5%; absence of circulating blasts; absence of extramedullary disease; no hematologic recovery required	Marrow should not merely be “aplastic”; bone marrow spicules should be present; at least 200 cells should be enumerated in the aspirate or cellularity should be at least 10% in the biopsy. Mainly used in the context of phase 1-2 clinical trials
PR	All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pre-treatment bone marrow blast percentage by at least 50%	Mainly used in the context of phase 1-2 clinical trials
No response	Patients evaluable for response but not meeting the criteria for CR, CRh, CRi, MLFS or PR are categorized as having no response prior to the response landmark. Patients failing to achieve response by the designated landmark are designated as having refractory disease	
Nonevaluable for response	Non-evaluable for response will include patients lacking an adequate bone marrow response evaluation. This category will include patients with early death, withdrawal prior to response assessment, or a technically suboptimal bone marrow sample precluding assessment	
Response (if including assessment of MRD)\$		
CR, CRh, or CRi without MRD‡ (CR _{MRD-} , CRh _{MRD-} , or CRi _{MRD-})	CR, CRh or CRi with MRD below a defined threshold for a genetic marker by qPCR, or by MFC. Response without MRD should be confirmed with a subsequent assessment at least 4 wk apart. The date of response without MRD is the first date in which the MRD was below the defined threshold Response with MRD detection at low-level (CR _{MRD-LL}) is included in this category of CR, CRh or CRi without MRD. CR _{MRD-LL} is currently only defined for <i>NPM1</i> -mutant and CBF-AML	Sensitivities vary by marker tested, and by method used; therefore, test used, tissue source and minimum assay sensitivity for evaluability should be reported; analyses should be done in experienced laboratories (centralized diagnostics)
Treatment failure		
Refractory disease	No CR, CRh or CRi at the response landmark, ie, after 2 courses of intensive induction treatment or a defined landmark, eg, 180 d after commencing less-intensive therapy	Patients not responding to a first cycle of 7 + 3 should be considered for a regimen containing higher doses of cytarabine
Relapsed disease (after CR, CRh or CRi)	Bone marrow blasts $\geq 5\%$; or reappearance of blasts in the blood in at least 2 peripheral blood samples at least one week apart; or development of extramedullary disease	

ANC, absolute neutrophil count; CBF, core-binding factor; VAF, variant allele frequency.

*To recognize the potential for continuing improvements in blood counts after myelosuppressive therapy, response definitions for patients with marrow blast clearance (< 5%) may be adjusted to reflect the best hematologic response achieved prior to commencement of the next treatment cycle. Aspirate reports that include MLFS, CRh, or CRi should note the potential for post-marrow blood counts to alter the final response designation. Patients should not have received G-CSF, nor platelet transfusions within 7 d prior to hematologic response determination.

†For patients with CR, CRh, or CRi, the presence of a low percentage of circulating blasts in the blood may represent a regenerating marrow and should not be interpreted as persistent disease. In such cases the blasts generally disappear within a week.

‡A response landmark for CR, CRh, or CRi should be stated, eg, after 2 cycles of intensive therapy; this landmark may be longer for nonintensive based treatment options, eg, 180 days.

\$MFC-MRD positivity is defined as $\geq 0.1\%$ of CD45 expressing cells with the target immunophenotype. MRD test positivity by qPCR is defined as cycling threshold (Ct) < 40 and is negative if Ct ≥ 40 in ≥ 2 of 3 replicates. In *NPM1*-mutated and CBF-AML, CR with molecular MRD detectable at low-level (CR_{MRD-LL}) defined as < 2% is designated as negative for MRD, because when measured at the end of consolidation treatment, is associated with a very low relapse rate.

Table 8. (continued)

Category	Definition	Comment
Treatment failure (if including assessment of MRD)[§] MRD relapse (after CR, CRh or CRi without MRD)	1. Conversion from MRD negativity to MRD positivity, independent of method, or 2. Increase of MRD copy numbers $\geq 1 \log_{10}$ between any two positive samples in patients with CR _{MRD-LL} , CRh _{MRD-LL} or CRi _{MRD-LL} by qPCR The result of 1. or 2. should be rapidly confirmed in a second consecutive sample from the same tissue source	Test methodology, sensitivity of the assay, and cutoff values used must be reported; analyses should be done in experienced laboratories (centralized diagnostics)

ANC, absolute neutrophil count; CBF, core-binding factor; VAF, variant allele frequency.

*To recognize the potential for continuing improvements in blood counts after myelosuppressive therapy, response definitions for patients with marrow blast clearance (< 5%) may be adjusted to reflect the best hematologic response achieved prior to commencement of the next treatment cycle. Aspirate reports that include MLFS, CRh, or CRi should note the potential for post-marrow blood counts to alter the final response designation. Patients should not have received G-CSF, nor platelet transfusions within 7 d prior to hematologic response determination.

†For patients with CR, CRh, or CRi, the presence of a low percentage of circulating blasts in the blood may represent a regenerating marrow and should not be interpreted as persistent disease. In such cases the blasts generally disappear within a week.

‡A response landmark for CR, CRh, or CRi should be stated, eg, after 2 cycles of intensive therapy; this landmark may be longer for nonintensive based treatment options, eg, 180 days.

§MFC-MRD positivity is defined as $\geq 0.1\%$ of CD45 expressing cells with the target immunophenotype. MRD test positivity by qPCR is defined as cycling threshold (Ct) < 40 and is negative if Ct ≥ 40 in ≥ 2 of 3 replicates. In *NPM1*-mutated and CBF-AML, CR with molecular MRD detectable at low-level (CR_{MRD-LL}) defined as < 2% is designated as negative for MRD, because when measured at the end of consolidation treatment, is associated with a very low relapse rate.

chemotherapy. The FDA defines maintenance therapy for AML as an extended but time-limited course of treatment, that is usually less toxic, given after achievement of CR with the objective of reducing the risk of relapse. Thus, a trial designed to demonstrate the efficacy of maintenance therapy would need to include a specified induction and consolidation treatment followed by randomization to a predefined duration of treatment.¹²⁹

The main objective of maintenance therapy is to deliver a minimally toxic therapy capable of reducing the risk of leukemic relapse. In a randomized study in newly diagnosed older patients in first remission after 2 cycles of intensive induction, azacitidine maintenance therapy, administered subcutaneously for up to 12 cycles, improved disease-free survival compared with no maintenance.¹³⁰ An orally administered version of azacitidine, CC-486, given over 14 days in 28-day cycles as continuous postremission therapy, was shown subsequently in a randomized placebo-controlled trial to reduce relapse risk and improve median OS (from 14.8 to 24.7 months) among patients ≥ 55 years not considered candidates for allogeneic HCT.¹³¹ Oral azacitidine prolonged OS independently of the MRD status as assessed by MFC (47% of patients were MRD positive and 53% were MRD negative at study entry).¹³² Oral azacitidine is approved for continued treatment of patients with AML in first CR/CRi following intensive induction chemotherapy who are not able to complete intensive curative therapy, including allogeneic HCT. However, there are limitations to the trial design that prohibit generalizability of the data.¹³³ First, data regarding the role of oral azacitidine in younger populations or patients with CBF-AML are lacking; furthermore, only few patients had AML with adverse-risk cytogenetics (14%). Second, because the trial did not specify prior induction and consolidation therapy, there was considerable variability in therapy prior to selection for

maintenance (ie, 45% of patients had received 1 consolidation cycle, 31% had 2 cycles, and 20% had no consolidation).

Patients who received midostaurin during induction and consolidation may continue these agents in maintenance in line with the reported phase 3 experience.¹⁰⁶

Patients not considered candidates for intensive therapy

There are no generally accepted or validated criteria to consider a patient ineligible for intensive chemotherapy. In the context of clinical trials, criteria have been used that consider a patient not eligible for intensive chemotherapy (for instance as defined in Table 11) that may also offer guidance in routine practice.

Substantial progress has been made in the management of patients considered unfit for intensive chemotherapy (Table 11). Compared with azacitidine alone, addition of the BCL2 inhibitor venetoclax improved clinical response (CR/CRi, 66.4% vs 28.3%) and median OS (14.7 vs 9.6 months), establishing a new standard of care for older or unfit patients with AML.¹³⁴ To limit prolonged myelosuppression and the risk of tumor lysis syndrome associated with this regimen, management recommendations are outlined in Table 12.¹³⁵ Although not evaluated in randomized clinical trials, phase 1b/2 studies suggest that clinical outcomes with decitabine plus venetoclax are similar to the azacitidine plus venetoclax combination.¹³⁶ For patients failing frontline venetoclax-based therapy, prognosis appears very poor.¹³⁷ For patients unable to receive a hypomethylating agent (HMA), low-dose cytarabine (LDC) in combination with venetoclax represents an alternative treatment option.¹³⁸ Although an open-label randomized study showed improved survival for the hedgehog inhibitor glasdegib in combination with LDC, compared with LDC alone, the relatively low response rate (CR/CRi 24%) with this regimen does not favor its use as an alternative nonintensive option.¹³⁹




Figure 2. Algorithm of MRD assessment and time points at which MRD is considered a clinically relevant biomarker. Blue squares indicate timepoints of assessment and source of material; pink squares indicate timepoints for treatment modification based on a clinical relevant biomarker: for example, if the level of molecular MRD as assessed by qPCR is $\geq 2\%$ or if there is failure to reduce mutant transcript levels by 3 to 4 log after completion of consolidation chemotherapy, treatment modifications (eg, allogeneic hematopoietic cell transplantation) may be considered; similarly, if patients are still MRD positive by MFC after 2 cycles of intensive chemotherapy or at end of treatment. For patients receiving less intensive therapy, timepoints for assessment and clinical decision making are not yet established. Modified from 2021 ELN MRD recommendations⁶⁷ BM, bone marrow; CBF, core-binding factor. ^aMFC as assessed by LAIP or the DfN method.

For newly diagnosed patients with *IDH1* mutation, results from a randomized study indicate that the *IDH1* inhibitor ivosidenib plus azacitidine improves EFS (hazard ratio, 0.33; 95% CI, 0.16–0.69), clinical response (CR/CRh, 52.8 vs 17.6%), and median OS (24.0 vs 7.9 months) compared with azacitidine plus placebo.¹⁴⁰ To identify patients suitable for ivosidenib at initial diagnosis, rapid *IDH1* mutation screening in older patients with AML is recommended. Patients with *IDH1/2*-mutated AML who are considered too frail to tolerate HMA-based treatment may be offered best supportive care or monotherapy with targeted *IDH1/IDH2* inhibitors.¹⁴¹

In patients receiving HMA-based combination therapy (with venetoclax, ivosidenib, other investigational agents), response should be assessed early during the first cycle (eg, on day 14–21) due to high rates of early responses seen with HMA combinations and the need to delay or modify dosing in the setting of persistent cytopenias in a leukemia-free marrow (Table 12). A second assessment is commonly performed after 3 cycles and then repeated every 3 cycles for patients in remission or at the discretion of the physician outside of a clinical trial. In the absence of treatment intolerance, nonintensive treatment approaches have commonly been continued until disease progression, but for the time being, there are no data supporting the advantage of an open-ended duration approach over therapy for a confined period.

Relapsed and refractory disease Common salvage regimens for patients with refractory or relapsed disease are given in

Table 10. At clinical progression, it is important to highlight the potential for clonal evolution and emergence of actionable targets not detected at diagnosis. Currently, these include emergence of *IDH1/IDH2* mutations or new or expanded *FLT3*-ITD or *FLT3* tyrosine kinase domain clones.^{142–146} Therefore, molecular re-evaluation at relapse is important to identify patients who may be suitable for targeted salvage options. In the interest of therapeutic progress, it is recommended to enter these patients into clinical trials whenever possible. Patients failing to achieve remission after 2 cycles of induction (including at least 1 cycle of intermediate-dose cytarabine) are defined as having primary refractory AML. Patients are unlikely to benefit from further cycles of conventional chemotherapy and instead should be referred for consideration of allogeneic HCT or participation in clinical trials.¹⁴⁷

Factors associated with reduced survival at AML relapse include shorter RFS ($< 6-12$ months), nonfavorable risk karyotype at diagnosis, older age ($> 45-55$ years), or prior history of HCT.^{148,149} In general, after cytoreduction has been achieved, allogeneic HCT is recommended. If HCT is not a realistic option (eg, in the older patient), disease control using a nonintensive option, such as HMA with or without venetoclax, may be appropriate. For patients with relapsed/refractory *FLT3*-mutated disease, the kinase inhibitor gilteritinib has been approved based on a randomized trial showing improved response rates (CR, 21.1% vs 10.5%) and median OS (9.3 vs 5.6 months) in the gilteritinib arm compared with physician's choice of salvage therapy.^{109,150} Although more patients receiving gilteritinib were bridged to

Table 9. Outcome measures for clinical trials in acute myeloid leukemia

Category	Definition
Early death	Death from any cause within a timeframe relevant for the therapy being investigated (eg, 30 and 60 d from commencing therapy)
Overall survival	Defined for all patients in a trial; measured from day 1 of randomization or day 1 of registration in non-randomized trials (or from the date of diagnosis, eg, for correlative science studies) to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive
Event-free survival (EFS)	Defined for all patients in a trial; measured from day 1 of randomization or day 1 of registration in non-randomized trials to the date of treatment failure, hematologic relapse from CR/CRh/CRi or death from any cause, whichever occurs first; treatment failure is defined as not achieving either CR, CRh or CRi by a pre-defined landmark (eg, after two cycles of intensive chemotherapy or 180 d for non-intensive therapy); patients evaluable for response but not achieving either CR, CRh or CRi by the defined landmark and patients who die before the defined landmark without response assessments are considered an event at day 1 of randomization; patients alive who are non-evaluable for response should be censored at day 1 of the randomization; patients achieving either CR, CRh or CRi by the defined landmark but do not relapse or die should be censored on the date they were last assessed for response
Relapse-free survival (RFS)*	Defined only for patients achieving CR, CRh, or CRi; measured from the date of achievement of remission until the date of hematologic relapse or death from any cause; patients not known to have relapsed or died at last follow-up are censored on the date they were last known to be alive
Cumulative incidence of relapse (CIR)	Defined for all patients achieving CR, CRh, CRi; measured from the date of achievement of a remission until the date of hematologic relapse; patients not known to have relapsed are censored on the date they were last assessed for response; patients who died without relapse are counted as a competing cause of failure
Cumulative incidence of death (CID)	Defined for all patients achieving CR, CRh, CRi; measured from the date of achievement of a remission to death without prior relapse; relapse is considered as competing risk
If including assessment of MRD relapse	
EFS _{MRD†}	Measured from day 1 of randomization or day 1 of registration in non-randomized trials to the date of failure to achieve CR, CRh or CRi by a defined landmark (eg, after two cycles of intensive chemotherapy or 180 d for non-intensive therapy), hematologic relapse, MRD relapse (for patients achieving CR, CRh or CRi without MRD) or death from any cause
RFS _{MRD†}	Measured from the date of achievement of a remission (CR, CRh, or CRi) until the date of hematologic relapse, MRD relapse, or death from any cause
CIR _{MRD†}	Measured from the date of achievement of a remission (CR, CRh or CRi) until the date of hematologic relapse, or molecular MRD relapse; patients who died without relapse are counted as a competing cause of failure
CID _{MRD}	Measured from the date of achievement of a remission (CR, CRh, or CRi) to death without prior relapse; morphologic or molecular MRD relapse is considered as competing risk

*Relapse-free and disease-free survival have been used with the same definition.

†Molecular MRD relapse should only consider data for mutated *NPM1*, *RUNX1::RUNX1T1* or *CBFB::MYH11* fusion transcripts as assessed by real-time quantitative PCR.

HCT (25.5% vs 15.3%) and these patients were permitted to restart gilteritinib 30 to 90 days after HCT, the clinical benefit of post-HCT gilteritinib remains uncertain. In addition, only 5.7% of patients received prior midostaurin as first-line therapy in this study, making generalization of treatment outcomes after this and other FLT3 inhibitors difficult. In a randomized trial evaluating the FLT3 inhibitor quizartinib in patients with relapsed/refractory FLT3-ITD-positive AML, quizartinib also showed improved OS compared with conventional care regimens.¹¹⁰ However, after evaluation of the trial data, neither FDA nor the European Medicines Agency granted approval.

For patients with relapsed/refractory IDH1/IDH2-mutant AML, salvage with ivosidenib or enasidenib is a possibility because

these IDH inhibitors induce CR rates in the range of 20% and overall response, including hematologic improvement in approximately 40%.¹⁵¹⁻¹⁵³ Median time required to attain CR is ~3 to 4 months, with 80% of cumulative responses attained after completion of 6 cycles of therapy.^{151,152} Among responders, molecular clearance with ivosidenib was observed in 21% and was associated with longer remission duration and prolonged survival.¹⁵¹ Although responders to enasidenib may also achieve molecular clearance, targeting IDH2 in a nonblinded randomized trial did not show improvement in OS compared with conventional care options among patients ≥60 years failing 2 or 3 prior lines of therapy.¹⁵⁴ For management of adverse events associated with novel agents, see the section on supportive care below and Table 12.

Allogeneic hematopoietic cell transplantation

AML is the most frequent indication for allogeneic HCT.^{155,156} Advances allowing for the use of partially matched unrelated donors, cord blood, and haplo-identical family members mean that an allogeneic donor can be found for most patients in need. Nonmyeloablative and reduced intensity conditioning (RIC) regimens make allogeneic HCT possible in patients up to age 80 at experienced centers.^{157,158} With newly approved methods to prevent and treat both infections and graft-versus-host disease (GVHD), outcomes following transplant continue to improve, leaving disease recurrence as the major cause of treatment failure.¹⁵⁹ Despite its central role in the management of adult AML, only a minority of patients for whom transplantation is indicated undergo the procedure.¹⁵⁶ Reasons for underutilization include biologic factors, personal and physician choice, and lack of access.¹⁶⁰

Indications for allogeneic HCT

The decision to perform allogeneic HCT during first remission depends on the risk-benefit ratio (ie, nonrelapse mortality [NRM] and disability/reduction in relapse risk) based on cytogenetic and molecular genetic features of disease at presentation and response to initial therapy, as well as patient, donor, and transplant factors. Allogeneic HCT should be considered when the relapse probability without the procedure is predicted to be >35% to 40%.¹²⁷ For patients with favorable-risk disease, allogeneic HCT in CR1 is generally not recommended except for those with inadequate clearance of MRD.^{69,161-163} In contrast, allogeneic HCT is recommended for patients with adverse-risk AML and for the majority of those with intermediate-risk disease, although quite a few centers rely on the presence of MRD to guide their decision based on the predicted risk of relapse. For patients who are age 60 or older, mostly based on retrospective comparisons, allogeneic HCT in first remission is recommended for those with intermediate-risk or adverse-risk disease willing and able to undergo remission-inducing therapy.^{164,165} Judicious patient selection is important in patients over 60 especially regarding the presence of comorbidities and support at home. Allogeneic HCT is the only curative therapy for patients with primary refractory disease and offers the best chance for cure in those who relapse after initial chemotherapy.¹⁶⁶ Other factors including comorbidities, donor source, and individual patient goals must be considered.

Comorbidities and risk scores

Several transplant-related models address the impact of comorbidities and disease risk.¹⁶⁷ The HCT comorbidity index (which has been modified to include age) sums a patient's comorbidities into a single score that predicts the likelihood of NRM following transplantation independent of the disease being treated.^{168,169} A disease-risk index based on disease-stage and cytogenetics predicts the likelihood of disease recurrence following transplantation independent of patient comorbidities.¹⁷⁰ The modified European Society of Blood and Marrow Transplantation risk score combines both patient and disease risk factors thus predicting OS rather than NRM or relapse risk.¹⁷¹

Preparative regimen intensity

Transplant preparative regimens run the gamut from nonmyeloablative, which would result in only mild, temporary depression of blood counts without transplant, to RIC regimens of varying intensity, to high-dose true MAC. Prospective randomized trials yield inconsistent results, but in general, NRM is increased, and relapse rates are diminished with higher-dose regimens. The best evidence supporting the use of MAC regimens in patients aged 18 to 65 years comes from the randomized phase 3 BMT CTN 0901 study, which showed improved survival with MAC compared with RIC because of a marked reduction in disease recurrence.^{172,173} In a retrospective analysis, the benefit of MAC was greatest in patients with genomic evidence of residual disease before transplant, as determined by NGS at the time of transplant.^{98,100}

Donor selection/GVHD prophylaxis

Registry analyses show approximate equivalence in outcomes for patients transplanted using a well-matched unrelated donor compared with those using a matched sibling donor.^{174,175} However, many patients lack a suitable sibling or volunteer unrelated donor. The recent demonstration that posttransplant cyclophosphamide GVHD prophylaxis is tolerable and results in encouraging outcomes using mismatched unrelated and haplo-identical donors substantially widens the donor pool.¹⁷⁶⁻¹⁷⁹ The use of single or double cord blood units with a high nucleated cell dose also results in excellent outcomes, particularly in patients with evidence of pretransplant MRD.^{179,180} Current data support the utilization of a matched sibling donor or well-matched unrelated donor as the preferred donor option in adults with AML.¹⁷⁷ Recognition of germline predisposition in the patient with AML and family members influences donor selection, and the use of relatives with deleterious germline variants should be avoided (see Germline predisposition). Randomized trials comparing outcome after transplantation using a matched unrelated donor vs a haplo-identical donor are underway.

Pre- and posttransplant strategies to prevent posttransplant relapse

Disease relapse is the major cause of treatment failure in adults allografted for AML.¹⁸¹ For patients who are in CR1 following 2 cycles of intensive therapy, there is no evidence that additional chemotherapy prior to transplantation reduces the risk of relapse regardless of pretransplant MRD status. There is increasing interest in the use of pharmacological or cellular therapy posttransplant to prevent disease recurrence. In patients allografted for FLT3-mutated AML, randomized studies show that maintenance with the FLT3 inhibitor sorafenib, although sometimes challenging to deliver, reduces the risk of relapse, suggesting that the use of a FLT3 inhibitor is a reasonable option.^{182,183} A randomized trial examining the benefit of posttransplant maintenance with the second-generation FLT3 inhibitor gilteritinib in this patient population is in progress. There is less evidence supporting the use of other agents as posttransplant maintenance in AML. A randomized study of maintenance using subcutaneous azacitidine showed no benefit and is not recommended based on available evidence¹⁸⁴; oral azacitidine (CC-486) is currently under study.

Table 10. Selected treatment options for patients fit for intensive chemotherapy

Fit for intensive chemotherapy	Induction	Consolidation*	Maintenance
AML with <i>FLT3</i> mutation	Daunorubicin 60 mg/m ² IV d1-3; or idarubicin 12 mg/m ² IV d1-3; and cytarabine 100-200 mg/m ² /d CIV d1-7; plus midostaurin 50 mg q12h PO d8-21 Re-induction: either 2nd cycle "7 + 3" or regimen containing higher dose of cytarabine, each plus midostaurin, preferable the latter in patients with no response to 1st cycle	3-4 cycles of IDAC 1000-1500 mg/m ² IV (500-1000 mg/m ² if ≥60 y old) over 3h q12h d1-3; plus midostaurin 50 mg q12h PO d8-21 (in all cycles)†	Midostaurin 50 mg q12h PO d1-28, q4 wk, over 12 cycles‡
Non- <i>FLT3</i> mutant§	Daunorubicin 60 mg/m ² IV d1-3, idarubicin 12 mg/m ² IV d1-3, or mitoxantrone 12 mg/m ² IV d1-3; and cytarabine 100-200 mg/m ² /d CIV d1-7 Re-induction: either 2nd cycle "7 + 3" or regimen containing higher dose of cytarabine, preferable the latter in patients with no response	3-4 cycles of IDAC 1000-1500 mg/m ² IV (500-1000 mg/m ² if ≥60 y old) over 3h q12h d1-3	Oral azacitidine 300 mg PO daily d1-14, q4 wk, until disease progression
Other options 			
Gemtuzumab ozogamicin (GO) for CD33-positive AML, favorable (or intermediate) cytogenetic risk	Daunorubicin 60 mg/m ² IV d1-3 and cytarabine 100-200 mg/m ² /d CIV d1-7; plus GO 3 mg/m ² (maximum dose 5 mg) IV, d1, 4, 7. GO is also widely administered on day 1 of induction only. Re-induction (if not in CR/CRh/CRi) may be with daunorubicin 60 mg/m ² IV d1-2 and cytarabine 1000 mg/m ² IV (500-1000 mg/m ² if ≥60 y old) over 3h q12h d1-3 without GO	2-4 cycles of IDAC 1000-1500 mg/m ² IV (500-1000 mg/m ² if ≥60 y old) over 3h q12h d1-3. GO 3 mg/m ² may be added on d1 (in up to 2 cycles). Consider omitting GO if allogeneic HCT is planned to reduce the risk of veno-occlusive disease.	
CPX-351 for AML with myelodysplasia-related changes or therapy-related AML¶	CPX-351 100 U/m ² (daunorubicin 44 mg/cytarabine 100 mg) IV d1, 3, 5 Re-induction (if not in CR/CRh/CRi): CPX-351 100 U/m ² IV d1, 3 only	1-2 cycles of CPX-351 65 U/m ² (daunorubicin 29 mg/cytarabine 65 mg) IV d1, 3	

CIV, continuous IV; IDAC, intermediate-dose cytarabine; PO, per os; QD, once daily; SC, subcutaneously.

*Results from assessment of MRD should be taken into account for selecting the appropriate consolidation therapy.

†In the trial that led to the regulatory approval of midostaurin for *FLT3*-mutated AML, consolidation cycles included high-dose cytarabine at 3000 mg/m², whereas intermediate dose levels of cytarabine (1000-1500 mg/m²) are nowadays more commonly applied in AML therapeutics.

‡The value of maintenance treatment with midostaurin remains uncertain.

§Alternative active frontline induction regimens that are sometimes used include FLAG-IDA (defined below under common salvage regimens).

||Data regarding the role of oral azacitidine maintenance therapy in younger patients (< 55 y) or patients with core-binding factor AML are lacking; in addition, data are lacking for oral azacitidine after GO-based or CPX-351 induction/consolidation therapy.

¶Data in younger adult patients (< 60 y) and for AML post myeloproliferative neoplasm are lacking. No benefit compared with "7 + 3" induction was shown in patients with antecedent MDS with prior hypomethylating agent exposure.

#Regimens containing higher doses of cytarabine are generally considered as the best option for patients not responding to a first cycle of "7 + 3." Single-agent IDAC should not be used in patients relapsing within 6 mo following consolidation with higher doses of cytarabine.

**Idarubicin may be replaced by mitoxantrone 10 mg/m² IV d2-4 (FLAG-MITO); or by amsacrine 100 mg/m² IV d2-4 (FLAG-AMSA).

††Gilteritinib as a salvage option has only been validated in a randomized trial after prior intensive chemotherapy.

‡‡Based on single-arm data.

§Although enasidenib did not show improved overall survival in a randomized study in comparison with conventional therapy in late-stage *IDH2*-mutant AML, clinically useful single-agent anti-leukemic activity has been demonstrated.

Table 10. (continued)

Common salvage regimens in patients not responding to initial induction or with relapsed disease who are candidates for intensive therapy	
Gilteritinib (AML with <i>FLT3</i> mutation)	Gilteritinib 120 mg PO QD d1-28, q4 wk, until disease progression
Intermediate-dose cytarabine# (with or without anthracycline)	Cytarabine 1000-1500 mg/m ² IV over 3h q12h d1-3 (500-1000 mg/m ² in patients ≥ 60y); with or without daunorubicin 60 mg/m ² IV d1-3; idarubicin 8-10 mg/m ² IV d3-5; or mitoxantrone 8-10 mg/m ² IV d1-3
FLAG-IDA**	Fludarabine 30 mg/m ² IV d2-6; cytarabine 1500-2000 mg/m ² IV over 3h, starting 4h after fludarabine infusion, d2-6; idarubicin 10 mg/m ² IV d2-4; G-CSF 5 µg/kg SC d1-5; additional G-CSF may be administered starting 7 d after end of chemotherapy until WBC count > 0.5 × 10 ⁹ /L Consider dose reduction in patients ≥60 y: fludarabine 20 mg/m ² ; cytarabine 500-1000 mg/m ² ; idarubicin 8 mg/m ²
MEC	Mitoxantrone 8 mg/m ² IV d1-5; etoposide 100 mg/m ² IV d1-5; cytarabine 1000 mg/m ² IV d1-5
CLAG-M	Cladribine 5 mg/m ² IV d1-5; cytarabine 2000 mg/m ² IV d1-5 (starting 2h after cladribine infusion); mitoxantrone 10 mg/m ² IV d1-3; G-CSF 300 µg SC d0-5
Allogeneic HCT	Consider transplantation for patients with primary refractory disease, for patients in second CR (or CRh, CRi) or with major cytoreduction but still active disease following salvage therapy. Consider second transplantation under certain conditions. Perform early HLA typing.
Salvage options if not a candidate for intensive chemotherapy	
Gilteritinib (AML with <i>FLT3</i> mutation)††	120 mg PO QD d1-28, q4 wk, until disease progression
Ivosidenib (AML with <i>IDH1</i> mutation)‡‡	500 mg PO QD d1-28, q4 wk, until disease progression
Enasidenib (AML with <i>IDH2</i> mutation) ^a	100 mg PO QD d1-28, q4 wk, until disease progression

CIV, continuous IV; IDAC; intermediate-dose cytarabine; PO, per os; QD, once daily; SC, subcutaneously.

*Results from assessment of MRD should be taken into account for selecting the appropriate consolidation therapy.

†In the trial that led to the regulatory approval of midostaurin for *FLT3*-mutated AML, consolidation cycles included high-dose cytarabine at 3000 mg/m², whereas intermediate dose levels of cytarabine (1000-1500 mg/m²) are nowadays more commonly applied in AML therapeutics.

‡The value of maintenance treatment with midostaurin remains uncertain.

\$Alternative active frontline induction regimens that are sometimes used include FLAG-IDA (defined below under common salvage regimens).

||Data regarding the role of oral azacitidine maintenance therapy in younger patients (< 55 y) or patients with core-binding factor AML are lacking; in addition, data are lacking for oral azacitidine after GO-based or CPX-351 induction/consolidation therapy.

¶Data in younger adult patients (< 60 y) and for AML post myeloproliferative neoplasm are lacking. No benefit compared with “7 + 3” induction was shown in patients with antecedent MDS with prior hypomethylating agent exposure.

#Regimens containing higher doses of cytarabine are generally considered as the best option for patients not responding to a first cycle of “7 + 3.” Single-agent IDAC should not be used in patients relapsing within 6 mo following consolidation with higher doses of cytarabine.

**Idarubicin may be replaced by mitoxantrone 10 mg/m² IV d2-4 (FLAG-MITO); or by amsacrine 100 mg/m² IV d2-4 (FLAG-AMSA).

††Gilteritinib as a salvage option has only been validated in a randomized trial after prior intensive chemotherapy.

‡‡Based on single-arm data.

^aAlthough enasidenib did not show improved overall survival in a randomized study in comparison with conventional therapy in late-stage *IDH2*-mutant AML, clinically useful single-agent anti-leukemic activity has been demonstrated.

Relapse after transplant

Ninety percent of those who relapse after an allogeneic HCT for AML do so by 2 years. The outcome of patients with morphologic relapse within the first 12 months is very poor, although a rapid taper of immunosuppression or donor lymphocyte infusion may salvage a proportion of patients with early molecular or cytogenetic relapse.^{185,186} For patients relapsing after an allogeneic HCT for *FLT3*-mutated AML, gilteritinib is the preferred treatment option with evidence of an emergent *FLT3* mutant clone. In the pivotal study, gilteritinib improved survival in patients with early relapses and was at least equivalent compared with intensive chemotherapy in relapses occurring beyond 6 months.^{109,150} Azacitidine, with or without donor lymphocyte infusion, and venetoclax-based salvage regimens may produce remissions in a small proportion of patients with less toxicity than intensive chemotherapy.¹⁸⁷ Those who achieve a second CR can sometimes still be cured with either donor lymphocyte infusion or a second allograft.¹⁸⁸

Clinical trials

It is recommended to enroll patients with AML onto clinical trials whenever a suitable trial opportunity is available. Real-time availability of rapid biomarker screening has become a basic requirement to enable timely enrollment of patients to clinical trials targeting defined AML subpopulations. Routine biobanking of patient samples should be standard practice to maximize clinical research.

Trial design

The execution of clinical trials for drug development in AML has become progressively challenging. There is an increasing number of novel AML therapeutics that warrant evaluation of safety and efficacy, in single agent and combination format, with many requiring prospective allocation to biologically defined genotypes. As AML is already a relatively rare disease, timely completion of adequately powered phase 3 clinical trials within smaller

Table 11. Selected treatment options for patients not suitable for intensive chemotherapy*

Regimen	Recommended dosing
Azacitidine or decitabine + venetoclax ^{†,‡}	Azacitidine 75 mg/m ² SC/IV d1-7 (alternatively d1-5 + d8-9) or decitabine 20 mg/m ² IV d1-5; venetoclax dose ramp up: 100 mg d1, 200 mg d2, 400 mg PO QD d3-28 <ul style="list-style-type: none"> Adjust venetoclax dose if concurrent strong CYP3A4 inhibitors: 10 mg on d1, 20 mg on d2, 50 mg on d3, 100 mg (or less[‡]) PO QD from d4 For venetoclax dose modifications and management of myelosuppression see Table 12
Low-dose cytarabine + venetoclax ^{†,‡}	Cytarabine 20 mg/m ² SC daily, d1-10; venetoclax dose ramp up: 100 mg d1, 200 mg d2, 400 mg d3, 600 mg d4-28 PO <ul style="list-style-type: none"> Adjust venetoclax dose if concurrent strong CYP3A4 inhibitors: 10 mg d1, 20 mg d2, 50 mg d3, 100 mg (or less[‡]) PO QD d4-28 For venetoclax dose modifications and management of myelosuppression see Table 12
Azacitidine + ivosidenib (AML with <i>IDH1</i> mutation)	Azacitidine 75 mg/m ² SC/IV d1-7 (alternatively d1-5 + d8-9); ivosidenib 500 mg PO QD d1-28; both q4 wk, until progression
Ivosidenib (AML with <i>IDH1</i> mutation)	For very frail patients, ivosidenib 500 mg PO QD d1-28 as monotherapy, until progression may be considered
Best supportive care	Including hydroxyurea; for patients who cannot tolerate any anti-leukemic therapy, or who do not wish any therapy

*For instance, criteria that have been used in clinical trials to select patients not suitable for intensive chemotherapy have been as follows: (1) age ≥ 75 y (however, this cannot be an absolute criterion; for instance, patients with more favorable disease and without relevant comorbidities may derive benefit from intensive chemotherapy) or (2) ECOG performance status > 2 and/or age-related comorbidities, such as severe cardiac disorder (eg, congestive heart failure requiring treatment, ejection fraction $\leq 50\%$, or chronic stable angina), severe pulmonary disorder (eg, DLCO $\leq 65\%$ or FEV1 $\leq 65\%$), creatinine clearance < 45 mL/min, hepatic disorder with total bilirubin > 1.5 times the upper limit of normal, or any other comorbidity that the physician assesses to be incompatible with intensive chemotherapy.

[†]To reduce the risk of tumor lysis syndrome, the prophylactic use of uric acid lowering drugs, close electrolyte monitoring and cytorreduction of the WBC to $< 25 \times 10^9/L$ or even lower, for patients with high bone marrow blast burden, elevated LDH is recommended.

[‡]In the VIALE-A and VIALE-C trials, an adjusted venetoclax dose of 50 mg was used in the presence of a strong CYP3A4 inhibitor. This venetoclax dose is supported by a pharmacokinetic study examining venetoclax in the presence of posaconazole.²⁰⁷

disease subsets has become more challenging, highlighting the growing need for intercontinental trials.

Early-phase clinical development

Innovation in clinical trial design is needed. Phase 1 exploration of new AML drugs in the relapsed/refractory setting remains a formidable task, with high levels of drug resistance, rapid disease progression, and complications related to severe cytopenias representing key hurdles to success. In such settings, a pharmacodynamic primary end point verifying the drug's proposed mechanism of action may represent an appropriate objective during the single agent dose-finding stage, followed by rapid transition to combination testing to demonstrate clinical efficacy. In phase 2, multiarm biomarker-stratified studies permitting parallel investigation of several drugs simultaneously will facilitate more efficient screening of new drugs and combinations for clinical activity.¹⁸⁹

Phase 3 trials

Randomized trials are the cornerstone of drug approval, especially in newly diagnosed patients. Accelerated recruitment to such trials is of central importance to improvements in outcome for patients with AML and yet paradoxically this remains a notoriously slow process. For example, the regulatory approval of midostaurin in 2017 for *FLT3*-mutant AML using OS as the primary study end point took almost a decade. The increasing number of new therapies in AML coupled with genomic stratification is creating significant challenges to the timely recruitment of patients to practice informing trials. As more effective salvage therapies are now available, the OS end point is complicated further by subsequent lines of AML-directed therapy;

crossover of patients from the control arm to novel agents has confounded the interpretation of OS increasingly in comparative studies (see "Outcome measures"). EFS as a primary study end point will not only eliminate the confounding effect of poststudy therapies, but as an additional advantage, it will shorten study completion timelines. In this regard, the use of the restricted "traditional" CR as one of the key events in EFS has become subject of debate. Because of frequent myelosuppression with novel drug combinations, and in addition, the need to proceed with therapy before full hematologic recovery, from a therapeutic point, it has become increasingly unrealistic to consider failure to attain CRh/CRi as events in EFS estimates even though the level of survival after CRh/CRi may be below that following CR.¹⁰¹ Another way of expediting earlier assessment of drug efficacy is to base outcomes on standardized MRD measurements.⁶⁷ To facilitate incorporation of MRD as an efficacy end point, CR (or CRh/CRi) with MRD response and EFS with molecular MRD relapse as an event represent promising new study end points. This will allow for direct comparisons between the quantitative depth of response of investigational and reference therapies as indicators of relative therapeutic value.

Acceleration of drug development could also benefit from using a validated control population, thus omitting the concurrent standard control arm so that all patients recruited to the trial receive investigational therapy. To realize such an approach, a well annotated and contemporary external reference cohort is required and efforts to establish real-world databases for this purpose are being explored. Finally, it remains of utmost importance to override geographic and interstudy group barriers and continue

Table 12. Novel agents: management of selected adverse events

Agent	AE requiring special attention (incidence all grades)	Management
Midostaurin	QT prolongation (10%)	Dose interruption/reduction, substitution of QT prolonging co-medication if possible, otherwise additional ECG controls
Gilteritinib	Transaminase elevation (81%) QT prolongation (9%) PRES (1%)	Dose interruption/reduction (if grade ≥ 3) Dose interruption/reduction, substitution of QT prolonging co-medication if possible Discontinuation
Ivosidenib	Differentiation syndrome (25% single agent, 17% in combination with azacitidine) QT prolongation (21% single agent, 26% combination with azacitidine)	Dexamethasone, hydroxyurea for co-occurring leukocytosis, Dose interruption/reduction Dose interruption/reduction, substitution of QT prolonging co-medication if possible
Enasidenib	Differentiation syndrome (14% single agent, 10% in combination with azacitidine) Bilirubin elevation (81%)	Dexamethasone, hydroxyurea for co-occurring leukocytosis, Dose interruption/reduction Dose interruption/reduction
Gemtuzumab ozogamicin	Transaminase elevation (24.5%)* Bilirubin elevation (13%)* VOD/SOS (2.9-4.6%)	Dose interruption/reduction Dose interruption, supportive care, fluid management, possibly defibrotide
Venetoclax	Neutropenia Thrombocytopenia Tumor lysis syndrome Interaction with CYP3A inhibitors	Early response assessment, eg, on day 14-21 of cycle 1, if bone marrow blasts $< 5\%$, cease venetoclax for up to 14 d to allow count recovery to \geq CRh. If neutropenia does not recover with 7 d of ceasing venetoclax, addition of G-CSF may augment recovery. Subsequent cycles: azacitidine 75 mg/m ² SC/IV d1-7 (or d1-5 + d8-9) or decitabine 20 mg/m ² IV d1-5 plus venetoclax 400 mg QD, or LDC 20 mg/m ² SC d1-10 plus venetoclax 600 mg QD q4 wk until progression. Delayed count recovery or recurrent treatment-emergent grade 4 neutropenia/thrombocytopenia lasting ≥ 7 d require reductions in the duration of administered venetoclax (from 28 to 21 or 14 d, or even less) and/or reductions in the dose of azacitidine, decitabine, or LDC if severe bone marrow hypoplasia. Dose ramp up in cycle 1; hydration, the prophylactic use of uric acid lowering drugs, close electrolyte monitoring and reduction of WBC to $< 25 \times 10^9/L$ ($< 25\,000/\mu L$) is recommended. <ul style="list-style-type: none"> Moderate CYP3A inhibitors (eg, ciprofloxacin): reduce the venetoclax dose by at least 50%; ramp-up phase: 50 mg on d1, 100 mg on d2, 200 mg PO QD from d3 Strong CYP3A inhibitors (eg, posaconazole): ramp-up phase: 10 mg on d1, 20 mg on d2, 50 mg on d3, 100 mg (or less[†])²⁰⁷ QD PO from d4.
Glasdegib	Muscle spasms (15%) QT prolongation (8.3%)	Dose interruption/reduction Dose interruption/reduction, substitution of QT prolonging co-medication if possible
CPX-351	Prolonged myelosuppression [†]	Consequent anti-infectious prophylaxis
CC-486/oral azacitidine	Neutropenia (44%) Thrombocytopenia (33%) Nausea (65%), vomiting (60%), diarrhea (50%)	Dose interruption/reduction, myeloid growth factors Prophylactic anti-emetics

AE, adverse event; LDC, low-dose cytarabine; PRES, posterior reversible encephalopathy syndrome; SmPC, Summary of Product Characteristics; SOS, sinusoidal obstructive syndrome, VOD, veno-occlusive disease.

*Single agent.

[†]Median times to absolute neutrophil count $\geq 0.5 \times 10^9/L$ ($\geq 500/\mu L$) were 35 and 29 days; and median times to platelet count $\geq 50 \times 10^9/L$ ($\geq 50\,000/\mu L$) were 36.5 and 29 days after CPX-351 vs "7 + 3," respectively, in patients who achieved CR/CRi after initial induction chemotherapy.

[‡]In the VIALE-A and VIALE-C trials, an adjusted venetoclax dose of 50 mg was used in the presence of a strong CYP3A4 inhibitor. This venetoclax dose is supported by a pharmacokinetic study examining venetoclax in the presence of posaconazole.²⁰⁷

efforts to stimulate the formation of “global” alliances and networks to expedite completion of registration-enabling clinical studies within a markedly condensed time window.

New therapies

Clinical investigation of new therapies and new combinations is of critical importance in continuing to improve AML patient outcomes.¹⁹⁰ Drug development strategies have focused until now primarily on single-agent dose finding studies in the relapsed setting, which have led to successful approvals of targeted therapies, such as FLT3, IDH1, and IDH2 inhibitors, and is the pattern for the current evaluation of menin inhibitors for patients with KMT2A rearrangements or NPM1 mutations.^{109,151,152,191}

Other agents (ie, epigenetically targeted therapies) and immunotherapy approaches including bi-specific T-cell engaging antibodies, checkpoint inhibitors, and chimeric antigen receptor T cells or natural killer cells are likely to be most effective in the setting of MRD, in frontline, or early salvage combination approaches.^{190,192,193} Although of limited single agent activity, the CD47 inhibitor magrolimab has demonstrated preliminary activity in combination with azacitidine in patients with newly diagnosed MDS and AML, even in the setting of TP53-mutated disease. Trials of various inhibitors of the CD47-SIRP- α macrophage checkpoint are currently under various stages of early clinical evaluation.¹⁹⁴

Due to the changing therapeutic environment, which now includes HMAs in combination with small molecule inhibitors like venetoclax or targeted therapies, future development of frontline combinations is now more complex. The evaluation of so-called “triplet” therapies is an increasingly common clinical trial design for “chemotherapy-ineligible” patients, which involves the evaluation of a third agent (either approved or investigational) to the HMA and venetoclax “backbone.” New combination trials in intensive chemotherapy eligible patients typically involve the incorporation of a new target or agent in combination with standard chemotherapy, such as the ongoing clinical trials of the FLT3 inhibitor gilteritinib with standard “7 + 3” vs “7 + 3” and midostaurin or the spleen tyrosine kinase (SYK) inhibitor with “7 + 3” vs “7 + 3” alone for NPM1-mutant AML.

In addition, oral formulations of the HMAs are now approved for AML maintenance (oral azacitidine)¹³¹ and high-risk MDS (oral decitabine/cedazuridine),¹⁹⁵ respectively, and given the increased patient convenience of oral formulations, it is likely that these agents will be increasingly used in future HMA-based combination trials.

Management of special situations and supportive care

A white blood cell count (WBC) $> 100 \times 10^9/L$ is generally defined as hyperleukocytosis and associated with increased induction mortality mainly due to hemorrhagic events, tumor lysis syndrome, and the risk for clinical leukostasis syndrome.¹⁹⁶ Hydroxyurea (up to 50-60 mg/kg per day) is most commonly used to lower the WBC below $25 \times 10^9/L$, particularly before the commencement of HMA- or venetoclax-based treatments. Clinical leukostasis syndrome is a medical emergency requiring

the WBC to be promptly lowered without delay by either hydroxyurea or planned induction therapy and a restrictive transfusion policy for red blood cells. Retrospective studies suggest a beneficial effect of dexamethasone, which may counteract effects of leukostasis.¹⁹⁷ Although leukapheresis may be performed in parallel with chemotherapy in patients with leukostasis syndrome,¹⁹⁸ current evidence does not support the use of leukapheresis in asymptomatic patients with hyperleukocytosis.^{199,200}

Other special situations requiring therapeutic intervention are the presence of disseminated intravascular coagulation (DIC), tumor lysis syndrome, and differentiation syndrome. DIC can be screened for using a scoring system and is present in 8.5% to 25% of patients with non-APL, with another ~15% also developing DIC soon after the initiation of chemotherapy.²⁰¹ Special attention to tumor lysis syndrome is required in patients with hyperleukocytosis or with venetoclax-based treatments (Table 12). Close monitoring for signs of differentiation syndrome such as unexplained fever, lung edema, weight gain, pulmonary infiltrates, hypoxia, and dyspnea is necessary, particularly in patients on treatment with IDH inhibitors.²⁰²

Supportive care

Anti-infectious prophylaxis

For prophylaxis and treatment of infections, prevailing institutional infectious organisms and their drug resistance pattern should be considered primarily. There is good evidence to recommend antifungal prophylaxis with posaconazole during remission induction therapy,²⁰³ whereas there is not enough evidence from randomized trials on antiviral prophylaxis for herpes simplex virus in patients with acute leukemia,²⁰⁴ and no evidence for a beneficial effect of *Pneumocystis jirovecii* pneumonia prophylaxis. For prophylaxis of infectious disease in the setting of allogeneic HCT, we refer to respective guidelines.²⁰⁵

Vaccination for influenza²⁰⁶ and COVID-19 viral infections is recommended for all patients to reduce the risk of severe infections.

The use of growth factors is not routinely recommended unless in individual patients (eg, in case of severe infections) or particular treatment settings (eg, to reduce the hematologic recovery times in consolidation cycles).^{1,122,123}

Transfusions

The availability of several effective novel agents may lead to a higher proportion of patients treated on an outpatient basis. If blood count checks are not possible at regular intervals in the outpatient setting, platelet and hemoglobin transfusion triggers should be elevated to ensure adequate support until the next outpatient visit. Besides the platelet count, mucosal bleeding, infection, severe mucositis, and fever should be considered in the assessment of bleeding risk and should increase the platelet level transfusion threshold. Otherwise, it is generally accepted to keep the hemoglobin level above 8 g/dL, and a platelet count of $<10 \times 10^9/L$ remains the trigger for prophylactic platelet transfusions.

Acknowledgments

The authors gratefully acknowledge Rüdiger Hehlmann for his continuous generous support of these recommendations on behalf of the

European LeukemiaNet and Partrycja Gradowska, Axel Benner, Maral Saadati, and Julia Krzykalla for reviewing the sections "Response criteria" and "Outcome measures."

H. Döhner is supported by SFB 1074 "Experimental models and clinical translation in leukemia" funded by the Deutsche Forschungsgemeinschaft. A.H.W. is supported by the Australian National Health and Medical Research Council, Victorian Cancer Agency, Metcalf Family Fellowship, and the Medical Research Future Fund. C.D.D. is supported by the LLS Scholar in Clinical Research award.

Clara Bloomfield, Elihu Estey and Francesco Lo-Coco have died since the publication of the 2017 ELN AML Recommendation edition. The authors acknowledge the impressive seminal contributions that Clara Bloomfield, Elihu Estey, and Francesco Lo-Coco made throughout many years to improve the treatment of AML and advance our understanding of the pathobiology of the disease. They were founding coauthors of the ELN AML Recommendation editions that first appeared in 2010 and (pro)actively participated with a high level of commitment in this endeavor. Each one in their own unique way contributed their invaluable clinical expertise, knowledge, and scientific rigor and were instrumental in establishing these recommendations as a widely accepted standard of reference.

Authorship

Contribution: All authors reviewed the literature and wrote first drafts of specific sections. H. Döhner and B.L. assembled the sections and wrote the final version of the manuscript. All authors reviewed and approved the final version of the manuscript.

Conflict-of-interest disclosure: H. Döhner had an advisory role with honoraria for AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, GEMOaB, Gilead, Janssen, Jazz, Novartis, Servier, and Syndax and received clinical research funding (to institution) from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, and Novartis. A.H.W. had an advisory role with honoraria for AbbVie, Agios, Amgen, Astellas, AstraZeneca, Roche, BMS, Celgene, Gilead, Pfizer, Janssen, Jazz, Novartis, and Servier; received clinical research funding (to institution) from AbbVie, Servier, Celgene-BMS, AstraZeneca, Amgen, and Novartis; and receives a fraction of royalty payments from the Walter and Eliza Hall Institute of Medical Research related to venetoclax. F.R.A. has consulted for Jasper Biotech. C.C. had an advisory role with honoraria for AbbVie, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, Daiichi-Sankyo, Eurocept, Gilead, Janssen, Jazz, and Novartis and received clinical research funding from AbbVie, Bristol Myers Squibb, Celgene, and Jazz Pharmaceuticals. C.D.D. received honoraria/consulting fees from AbbVie, Agios/Servier, Astellas, Celgene/BMS, Cleave, Foghorn, Genentech, GenMab, GSK, Novartis, Notable Labs, Takeda and research grants (to institution) from AbbVie, Agios/Servier, Astex, Calithera, Celgene/BMS, Cleave, Foghorn, ImmuneOnc, and Loxo. H. Dombret received honoraria/consulting fees from AbbVie, Amgen, Astellas, Celgene-BMS, Daiichi Sankyo, Incyte, Jazz Pharmaceuticals, Pfizer, and Servier and research funding from Amgen, Astellas, Celgene-BMS, Incyte, Jazz Pharmaceuticals, and Pfizer. B.L.E. received consulting fees from GRAIL and research funding from Celgene, Deerfield, Novartis, and Calico and is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics. P.F. received honoraria and, as French MDS group chairperson, research support from Celgene/BMS, Novartis, AbbVie, Jazz, Janssen, and Agios. R.A.L. has been a consultant or advisor to Amgen, Ariad/Takeda, Astellas, Celgene/BMS, CVS/Caremark, Epizyme, Immunogen, MedPace, MorphoSys,

Novartis, and Servier and has received clinical research support to his institution from Astellas, Celgene, Cellectis, Daiichi Sankyo, Forty Seven/Gilead, Novartis, Rafael Pharmaceuticals and royalties from UpToDate. R.L.L. was on the supervisory board of Qiagen and an scientific advisor to Imago, Mission Bio, Zentalis, Ajax, Auron, Prelude, C4 Therapeutics, and Isoplexis, for which he receives equity; received research support from Calico, Constellation, Zentalis, and Ajax; consulted for Incyte, Janssen, Morphosys, and Novartis; and received honoraria from Roche, Lilly, and Amgen for invited lectures and from Gilead for grant reviews. Y.M. received honoraria from Nippon-Shinyaku, Bristol-Myers Squibb, Novartis, Sumitomo Pharma, Kyowa-Kirin, AbbVie, Daiichi-Sankyo, Takeda, Janssen Pharmaceutical, Astellas, Pfizer, Eisai, and Otsuka Pharmaceutical and research funding from Sumitomo-Dainippon. G.O. had an advisory role with honoraria for AbbVie, Astellas, Bristol Myers Squibb, Celgene, Gilead, Servier, JAZZ, and Novartis. C.R. had an advisory role with honoraria for AbbVie, Amgen, Astellas, BMS, Celgene, Jazz, Novartis, Pfizer, and Servier and received clinical research funding from AbbVie, Novartis, and Pfizer. J.S. had an advisory role with honoraria for AbbVie, Astellas, AstraZeneca, Berlin-Chemie, Celgene, AvenCell-GEMOaB, Janssen, Jazz Pharmaceuticals, Novartis, and Bristol Myers Squibb and received clinical research funding from AbbVie, Astellas, Jazz Pharmaceuticals, and Jose Carreras International Leukemia Foundation. E.M.S. was on the advisory board for Novartis, PinotBio, Janssen, Bristol Myers Squibb, Agios, Jazz, Menarini, Genentech, Genesis, AbbVie, Neoleukin, Gilead, Syndax, OnCusp, CTI Biopharma, Foghorn, Servier, Calithera, Daiichi, Aptose, Syros, Astellas, Ono Pharma, and Blueprint; received honoraria from Kura; performed safety monitoring for Epizyme and Cellectis; and received research funding for Eisai and Bristol Myers Squibb and equity from Auron. M.S.T. was on the advisory boards for AbbVie, Daiichi-Sankyo, Orsenix, KAHN, Oncolyze, Jazz Pharma, Roche, Biosight, Novartis, Innate Pharmaceuticals, Kura, Syros Pharmaceuticals, Ipsen Biopharmaceuticals, and Cellularity and received research funding from AbbVie, Orsenix, Biosight, Gylcomimetics, Rafael Pharmaceuticals, and Amgen and royalties from UpToDate. H.-F.T. had an advisory role with honoraria for AbbVie, Alexion, Celgene, Daiichi Sankyo, Novartis, and Roche and received research funding from Celgene. J.W. had an advisory role with honoraria for AbbVie. A.W. had an advisory role with honoraria for AbbVie, Astellas, BMS, Celgene, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, and Servier and received clinical research funding from Jazz Pharmaceuticals. B.L. had an advisory role with honoraria for AbbVie, Astellas, Bristol Myers Squibb/Celgene, Catamaran Bio, AvenCell/GEMOaB, Frame Pharmaceuticals, Gilead, Kronos Bio, Oxford Biomedica, and Servier/Agios and received royalties from UpToDate and equity from Frame Pharmaceuticals. All remaining authors declare no competing financial interests.

ORCID profiles: H. Döhner, 0000-0003-2116-5536; A.H.W., 0000-0002-7514-3298; C.D.D., 0000-0001-9003-0390; B.L.E., 0000-0003-0197-5451; R.P.H., 0000-0002-7753-0697; R.A.L., 0000-0001-9168-3203; J.S., 0000-0002-7966-0356; J.W., 0000-0001-9437-9151; A.W., 0000-0001-7909-457X; B.L., 0000-0001-8982-5217.

Correspondence: Hartmut Döhner, Department of Internal Medicine III, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany; e-mail: hartmut.doehner@uniklinik-ulm.de.

Footnotes

Submitted 29 April 2022; accepted 29 June 2022; prepublished online on *Blood* First Edition 7 July 2022. DOI 10.1182/blood.2022016867.

There is a *Blood* Commentary on this article in this issue.

REFERENCES

- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of acute myeloid leukemia in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
- Arber DA, Orazi A, Hasserjian RP, et al. The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228.
- Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. 2010; 115(3):453-474.
- Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. *Blood*. 2019;133(15):1630-1643.

5. Ley TJ, Miller C, Ding L, et al; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-2074.
6. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. 2016;374(23):2209-2221.
7. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. *Science*. 2019;366(6465):eaan4673.
8. Arber DA, Hasserjian RP, Orazi A, et al. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. *Am J Hematol*. 2022;97(5): 514-518.
9. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405.
10. Cui W, Sun J, Cotta CV, Medeiros LJ, Lin P. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. *Am J Clin Pathol*. 2011;136(2): 282-288.
11. Haferlach C, Bacher U, Haferlach T, et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. *Leukemia*. 2011; 25(5):874-877.
12. Ok CY, Hasserjian RP, Fox PS, et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. *Leukemia*. 2014; 28(1):185-189.
13. Rogers HJ, Vardiman JW, Anastasi J, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. *Haematologica*. 2014;99(5):821-829.
14. Kayser S, Hills RK, Langova R, et al. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. *Br J Haematol*. 2021;192(5):832-842.
15. Fang H, Yabe M, Zhang X, et al. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. *Mod Pathol*. 2021;34(6):1143-1152.
16. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, et al. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. *Blood Adv*. 2019; 3(6):922-933.
17. Patel SS, Ho C, Ptashkin RN, et al. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. *Blood Adv*. 2019;3(9):1540-1545.
18. Forghieri F, Nasillo V, Paolini A, et al. NPM1-mutated myeloid neoplasms with <20% blasts: a really distinct clinico-pathologic entity? *Int J Mol Sci*. 2020; 21(23):8975.
19. Foucar K, Anastasi J. Acute myeloid leukemia with recurrent cytogenetic abnormalities. *Am J Clin Pathol*. 2015; 144(1):6-18.
20. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. *Blood*. 1997;90(8):2969-2977.
21. DiNardo CD, Garcia-Manero G, Pierce S, et al. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). *Am J Hematol*. 2016;91(2):227-232.
22. Toth LN, Green D, Peterson J, Deharvenge SJ, de Abreu FB, Loo EY. Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup. *Leuk Lymphoma*. 2019;60(10):2415-2422.
23. Chen X, Othus M, Wood BL, et al. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. *Leuk Lymphoma*. 2021;62(5): 1226-1233.
24. Estey E, Hasserjian RP, Döhner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. *Blood*. 2022;139(3):323-332.
25. DiNardo CD, Garcia-Manero G, Kantarjian HM. Time to blur the blast boundaries. *Cancer*. 2022;128(8):1568-1570.
26. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood*. 2015;125(9):1367-1376.
27. Miesner M, Haferlach C, Bacher U, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). *Blood*. 2010;116(15): 2742-2751.
28. Weinberg OK, Gibson CJ, Blonquist TM, et al. Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. *Haematologica*. 2018;103(4): 626-633.
29. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, et al. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. *Am J Hematol*. 2020;95(6): 612-622.
30. Duhoux FP, Ameye G, Montano-Almendras CP, et al; Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO). PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. *Br J Haematol*. 2012;156(1):76-88.
31. Ottema S, Mulet-Lazaro R, Beverloo HB, et al. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. *Blood*. 2020; 136(2):224-234.
32. Tarlock K, Lamble AJ, Wang YC, et al. CEBPA bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group [published correction appears in *Blood*. 2022;139(10):1601]. *Blood*. 2021;138(13): 1137-1147.
33. Sierra J, Nomdedeu JF. CEBPA bZip mutations: just a single shot. *Blood*. 2021; 138(13):1091-1092.
34. Taube F, Georgi JA, Kramer M, et al; Study Alliance Leukemia (SAL). CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. *Blood*. 2022; 139(1):87-103.
35. Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. *Blood Adv*. 2022;6(1):238-247.
36. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. *Blood*. 2012;119(9):2114-2121.
37. Middeke JM, Herold S, Rücker-Braun E, et al; Study Alliance Leukaemia (SAL). TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. *Br J Haematol*. 2016;172(6):914-922.
38. Montalban-Bravo G, Benton CB, Wang SA, et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. *Blood*. 2017;129(18):2584-2587.
39. Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. *Blood Adv*. 2020;4(22):5681-5689.
40. Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood*. 2022; 139(15):2347-2354.
41. Weinberg OK, Siddon A, Madanat YF, et al. TP53 mutation defines a unique

- subgroup within complex karyotype de novo and therapy-related MDS/AML. *Blood Adv.* 2022;6(9):2847-2853.
42. Gardin C, Pautas C, Fournier E, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. *Blood Adv.* 2020;4(9):1942-1949.
 43. Richardson DR, Swoboda DM, Moore DT, et al. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia. *Am J Hematol.* 2021;96(4):462-470.
 44. van der Werf I, Wojtuszkiewicz A, Meggendorfer M, et al. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. *Blood Adv.* 2021;5(17):3254-3265.
 45. Awada H, Durmaz A, Gurnari C, et al. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia [published correction appears in *Blood.* 2022;139(9):1424-1425]. *Blood.* 2021;138(19):1885-1895.
 46. Fang H, He R, Chiu A, et al. Genetic factors in acute myeloid leukemia with myelodysplasia-related changes. *Am J Clin Pathol.* 2020;153(5):656-663.
 47. Morton LM, Dore GM, Schonfeld SJ, et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. *JAMA Oncol.* 2019;5(3):318-325.
 48. Voso MT, Falconi G, Fabiani E. What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms. *Blood.* 2021;138(9):749-757.
 49. McNeerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. *Nat Rev Cancer.* 2017;17(9):513-527.
 50. Schwartz JR, Ma J, Kamens J, et al. The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. *Nat Commun.* 2021;12(1):985.
 51. Ok CY, Patel KP, Garcia-Manero G, et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. *Leuk Res.* 2015;39(3):348-354.
 52. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature.* 2015;518(7540):552-555.
 53. Patel AA, Rojek AE, Drazer MW, et al. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. *Blood Adv.* 2021;5(20):4140-4148.
 54. Soerensen JF, Aggerholm A, Kerndrup GB, et al. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. *Blood Adv.* 2020;4(5):885-892.
 55. Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. *Cell Stem Cell.* 2017;21(3):374-382.e4.
 56. Swisher EM, Harrell MI, Norquist BM, et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. *JAMA Oncol.* 2016;2(3):370-372.
 57. Pharoah PDP, Song H, Dicks E, et al; Ovarian Cancer Association Consortium. PPM1D mosaic truncating variants in ovarian cancer cases may be treatment-related somatic mutations. *J Natl Cancer Inst.* 2016;108(3):djv347.
 58. Churpek J, Marquez R, Neistadt B, et al. Inherited mutations in cancer susceptibility genes are common among breast cancer survivors who develop therapy-related leukemia. *Cancer.* 2016;122(2):304-311.
 59. Schulz E, Valentin A, Ulz P, et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. *J Med Genet.* 2012;49(7):422-428.
 60. Qin N, Wang Z, Liu Q, et al. Pathogenic germline mutations in DNA repair genes in combination with cancer treatment exposures and risk of subsequent neoplasms among long-term survivors of childhood cancers. *J Clin Oncol.* 2020;38(24):2728-2740.
 61. Weinberg OK, Kuo F, Calvo KR. Germline predisposition to hematolymphoid neoplasia. *Am J Clin Pathol.* 2019;152(3):258-276.
 62. Trotter AM, Godley LA. Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. *Br J Haematol.* 2021;194(4):663-676.
 63. Roloff GW, Drazer MW, Godley LA. Inherited susceptibility to hematopoietic malignancies in the era of precision oncology. *JCO Precis Oncol.* 2021;5(5):107-122.
 64. Rafei H, DiNardo CD. Hereditary myeloid malignancies. *Best Pract Res Clin Haematol.* 2019;32(2):163-176.
 65. Yang F, Long N, Anekpitanang T, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. *Blood.* 2022;139(8):1208-1221.
 66. Gibson CJ, Kim HT, Zhao L, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. *J Clin Oncol.* 2022;40(2):189-201.
 67. Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. *Blood.* 2021;138(26):2753-2767.
 68. Ivey A, Hills RK, Simpson MA, et al; UK National Cancer Research Institute AML Working Group. Assessment of minimal residual disease in standard-risk AML. *N Engl J Med.* 2016;374(5):422-433.
 69. Balsat M, Renneville A, Thomas X, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. *J Clin Oncol.* 2017;35(2):185-193.
 70. Kapp-Schwoerer S, Weber D, Corbacioglu A, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. *Blood.* 2020;136(26):3041-3050.
 71. Döhner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. *Blood.* 2020;135(5):371-380.
 72. Angenendt L, Röllig C, Montesinos P, et al. Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts. *J Clin Oncol.* 2019;37(29):2632-2642.
 73. Lugthart S, Gröschel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *J Clin Oncol.* 2010;28(24):3890-3898.
 74. Chilton L, Hills RK, Harrison CJ, Burnett AK, Grimwade D, Moorman AV. Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. *Leukemia.* 2014;28(2):321-328.
 75. Walter RB, Ofan Y, Wierzbowska A, et al. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. *Leukemia.* 2021;35(6):1529-1538.
 76. Dillon R, Potter N, Freeman S, Russell N. How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). *Br J Haematol.* 2021;193(2):231-244.
 77. Vonk CM, Al Hinai ASA, Hanekamp D, Valk PJM. Molecular minimal residual disease detection in acute myeloid leukemia. *Cancers (Basel).* 2021;13(21):5431.
 78. Wood B, Jevremovic D, Béné MC, Yan M, Jacobs P, Litwin V; ICSH/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. *Cytometry B Clin Cytom.* 2013;84(5):315-323.
 79. Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ. Immunophenotypic detection of measurable residual (stem cell) disease using LAIP approach in acute myeloid leukemia. *Curr Protoc Cytom.* 2019;91(1):e66.
 80. Zeijlemaker W, Grob T, Meijer R, et al. CD34⁺CD38⁺ leukemic stem cell frequency

- to predict outcome in acute myeloid leukemia. *Leukemia*. 2019;33(5):1102-1112.
81. Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. *Int J Hematol*. 2017; 105(5):549-557.
 82. Ommen HB. Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. *Ther Adv Hematol*. 2016;7(1):3-16.
 83. Ghannam J, Dillon LW, Hourigan CS. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. *Br J Haematol*. 2020;188(1): 77-85.
 84. Heuser M, Heida B, Büttner K, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. *Blood Adv*. 2021;5(9):2294-2304.
 85. Cappelli LV, Meggendorfer M, Baer C, et al. Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. *Leukemia*. 2022; 36(2):394-402.
 86. Hasserjian RP, Steensma DP, Graubert TA, Ebert BL. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. *Blood*. 2020; 135(20):1729-1738.
 87. Short NJ, Zhou S, Fu C, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. *JAMA Oncol*. 2020;6(12): 1890-1899.
 88. Maiti A, DiNardo CD, Wang SA, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. *Blood Adv*. 2021; 5(7):1876-1883.
 89. Pratz KW, Jonas BA, Pullarkat V, et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. *J Clin Oncol*. 2022;40(8):855-865.
 90. Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol*. 2013; 31(31):3889-3897.
 91. Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. *N Engl J Med*. 2018;378(13):1189-1199.
 92. Freeman SD, Hills RK, Virgo P, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. *J Clin Oncol*. 2018;36(15): 1486-1497.
 93. Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. *Blood*. 2019;134(12):935-945.
 94. Willekens C, Blanchet O, Renneville A, et al; French AML InterGroup. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. *Haematologica*. 2016;101(3):328-335.
 95. Rücker FG, Agrawal M, Corbacioglu A, et al. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. *Blood*. 2019;134(19): 1608-1618.
 96. Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia [published correction appears in *Blood Adv*. 2022;6(5):1489]. *Blood Adv*. 2021;5(23):5107-5111.
 97. Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. *Leukemia*. 2015;29(1):137-144.
 98. Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. *J Clin Oncol*. 2020; 38(12):1273-1283.
 99. Craddock C, Jackson A, Loke J, et al. Augmented reduced-intensity regimen does not improve posttransplant outcomes in acute myeloid leukemia. *J Clin Oncol*. 2021;39(7):768-778.
 100. Paras G, Morsink LM, Othus M, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. *Blood*. 2022;139(11):1694-1706.
 101. Norsworthy KJ, Gao X, Ko C-W, et al. Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses. *J Clin Oncol*. 2022;40(8):847-854.
 102. Röhl C, Kramer M, Schliemann C, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? *Blood*. 2020;136(7):823-830.
 103. Kayser S, Döhner K, Krauter J, et al; German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. *Blood*. 2011; 117(7):2137-2145.
 104. Kröger N, Brand R, van Biezen A, et al; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT). Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. *Haematologica*. 2009;94(4):542-549.
 105. Jentzsch M, Grimm J, Bill M, et al. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2021;56(4):936-945.
 106. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. *N Engl J Med*. 2017;377(5):454-464.
 107. Larson RA, Mandrekar SJ, Huebner LJ, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. *Leukemia*. 2021;35(9):2539-2551.
 108. Döhner H, Weber D, Krzykalla J, et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications [published online ahead of print 29 June 2022]. *Blood Adv*. doi:10.1182/bloodadvances.2022007223.
 109. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. *N Engl J Med*. 2019;381(18):1728-1740.
 110. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib vs salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(7):984-997.
 111. Erba H, Montesinos P, Vrhovac R, et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML. *HemaSphere*. 2022;6:S100.
 112. Castaigne S, Pautas C, Terré C, et al; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. *Lancet*. 2012; 379(9825):1508-1516.
 113. Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. *Haematologica*. 2019; 104(1):113-119.
 114. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. *Lancet Oncol*. 2014;15(9):986-996.
 115. Schlenk RF, Paschka P, Krzykalla J, et al. Gemtuzumab ozogamicin in NPM1-mutated AML: Results from the prospective randomized AMLSG 09-09 phase-III study. *J Clin Oncol*. 2020;38(6):623-632.
 116. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. *J Clin Oncol*. 2011;29(4):369-377.
 117. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival

- in older patients with acute myeloid leukemia. *J Clin Oncol*. 2012;30(32):3924-3931.
118. Lim W-S, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. *Leuk Res*. 2010;34(9):1214-1223.
 119. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection vs conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. *J Clin Oncol*. 2018;36(26):2684-2692.
 120. Lancet JE, Uy GL, Newell LF, et al. CPX-351 vs 7 + 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. *Lancet Haematol*. 2021;8(7):e481-e491.
 121. Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. *Blood*. 2013;121(1):26-28.
 122. Jaramillo S, Benner A, Krauter J, et al. Condensed vs standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. *Blood Cancer J*. 2017;7(5):e564-e564.
 123. Dumas PY, Bertoli S, Bérard E, et al. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. *Blood Adv*. 2020;4(16):3840-3849.
 124. Schaich M, Röhl C, Soucek S, et al. Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. *J Clin Oncol*. 2011;29(19):2696-2702.
 125. Löwenberg B, Pabst T, Vellenga E, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. *N Engl J Med*. 2011;364(11):1027-1036.
 126. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. *J Clin Oncol*. 2013;31(27):3360-3368.
 127. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. *Blood*. 2016;127(1):62-70.
 128. Ferrara F, Picardi A. Is there still a role for autologous stem cell transplantation for the treatment of acute myeloid leukemia? *Cancers (Basel)*. 2019;12(1):59.
 129. US Food and Drug Administration. 2020, Guidance for industry. Acute myeloid leukemia: developing drugs and biological products for treatment. Available at: <https://www.fda.gov/media/140821/>. Accessed 30 June 2022.
 130. Huls G, Chitu DA, Havelange V, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. *Blood*. 2019;133(13):1457-1464.
 131. Wei AH, Döhner H, Pocock C, et al; QUAZAR AML-001 Trial Investigators. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. *N Engl J Med*. 2020;383(26):2526-2537.
 132. Roboz GJ, Ravandi F, Wei AH, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. *Blood*. 2022;139(14):2145-2155.
 133. Jen EY, Wang X, Li M, et al. FDA approval summary: oral azacitidine for continued treatment of adults with acute myeloid leukemia unable to complete intensive curative therapy. *Clin Cancer Res*. 2022;28(14):2989-2993.
 134. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med*. 2020;383(7):617-629.
 135. DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. *Blood*. 2020;135(2):85-96.
 136. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. *Blood*. 2019;133(1):7-17.
 137. Maiti A, Rausch CR, Cortes JE, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. *Haematologica*. 2021;106(3):894-898.
 138. Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. *Blood*. 2020;135(24):2137-2145.
 139. Cortes JE, Heideel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. *Leukemia*. 2019;33(2):379-389.
 140. Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in previously untreated IDH1-mutated acute myeloid leukemia. *N Engl J Med*. 2022;386(16):1519-1531.
 141. Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. *Blood*. 2020;135(7):463-471.
 142. DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. *Blood*. 2020;135(11):791-803.
 143. Intlekofer AM, Shih AH, Wang B, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. *Nature*. 2018;559(7712):125-129.
 144. Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. *Cancer Discov*. 2018;8(12):1540-1547.
 145. McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. *Cancer Discov*. 2019;9(8):1050-1063.
 146. Schmalbrock LK, Dolnik A, Cocciardi S, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. *Blood*. 2021;137(22):3093-3104.
 147. Ferguson P, Hills RK, Grech A, et al; UK NCRI AML Working Group. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. *Haematologica*. 2016;101(11):1351-1358.
 148. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. *J Clin Oncol*. 2005;23(9):1969-1978.
 149. Ganzel C, Sun Z, Cripe LD, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. *Am J Hematol*. 2018;93(8):1074-1081.
 150. Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. *Blood*. 2022;139(23):3366-3375.
 151. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. *N Engl J Med*. 2018;378(25):2386-2398.
 152. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. *Blood*. 2017;130(6):722-731.
 153. Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. *Blood*. 2019;133(7):676-687.
 154. de Botton S, Montesinos P, Schuh AC, et al. Enasidenib vs conventional care regimens in older patients with late-stage mutant-IDH2 relapsed/refractory acute myeloid leukemia: a randomized phase 3 trial [published online ahead of print 17 June 2022]. *Blood*. doi:10.1182/blood.2021014901.
 155. Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. *Haematologica*. 2022;107(5):1045-1053.

156. D'Souza A, Fretham C, Lee SJ, et al. Current use of and trends in hematopoietic cell transplantation in the United States. *Biol Blood Marrow Transplant*. 2020;26(8):e177-e182.
157. Appelbaum FR. Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia. *Best Pract Res Clin Haematol*. 2021;34(4):101320.
158. Ringdén O, Boumendis A, Labopin M, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2019;25(10):1975-1983.
159. McDonald GB, Sandmaier BM, Mielcarek M, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 vs 2013-2017 cohorts. *Ann Intern Med*. 2020;172(4):229-239.
160. Eapen M. Since everyone has a donor, why are some eligible patients still not transplanted? *Best Pract Res Clin Haematol*. 2021;34(4):101321.
161. Dholaria B, Savani BN, Hamilton BK, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. *Transplant Cell Ther*. 2021;27(1):6-20.
162. Pollyea DA, Bixby D, Perl A, et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. *J Natl Compr Canc Netw*. 2021;19(1):16-27.
163. Loke J, Buka R, Craddock C. Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how? *Front Immunol*. 2021;12:659595.
164. Ustun C, Le-Rademacher J, Wang HL, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. *Leukemia*. 2019;33(11):2599-2609.
165. Russell NH, Hills RK, Thomas A, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. *Haematologica*. 2021;107(7):1518-1527.
166. Heinicke T, Kahl R, Kahl C, et al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. *Ann Hematol*. 2021;100(9):2387-2398.
167. Potdar R, Varadi G, Fein J, Labopin M, Nagler A, Shouval R. Prognostic scoring systems in allogeneic hematopoietic stem cell transplantation: where do we stand? *Biol Blood Marrow Transplant*. 2017;23(11):1839-1846.
168. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*. 2005;106(8):2912-2919.
169. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. *J Clin Oncol*. 2014;32(29):3249-3256.
170. Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. *Blood*. 2012;120(4):905-913.
171. Shouval R, Bondi O, Mishan H, Shimoni A, Unger R, Nagler A. Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT. *Bone Marrow Transplant*. 2014;49(3):332-337.
172. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative vs reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. *J Clin Oncol*. 2017;35(11):1154-1161.
173. Scott BL, Pasquini MC, Fei M, et al. Myeloablative vs reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes - long-term follow-up of the BMT CTN 0901 clinical trial. *Transplant Cell Ther*. 2021;27(6):483.e1-483.e6.
174. Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. *Blood*. 2019;134(12):924-934.
175. Woolfrey A, Lee SJ, Gooley TA, et al. HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. *Biol Blood Marrow Transplant*. 2010;16(10):1382-1387.
176. Kasamon YL, Bolaños-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. *J Clin Oncol*. 2015;33(28):3152-3161.
177. Gooptu M, Romee R, St Martin A, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. *Blood*. 2021;138(3):273-282.
178. Shaw BE, Jimenez-Jimenez AM, Burns LJ, et al. National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. *J Clin Oncol*. 2021;39(18):1971-1982.
179. Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. *N Engl J Med*. 2016;375(10):944-953.
180. Barker JN, Devlin SM, Naputo KA, et al. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. *Blood Adv*. 2020;4(23):6064-6076.
181. Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. *Br J Haematol*. 2020;188(1):129-146.
182. Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). *J Clin Oncol*. 2020;38(26):2993-3002.
183. Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. *Lancet Oncol*. 2020;21(9):1201-1212.
184. Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients [published correction appears in *Blood Adv*. 2021;5(6):1755-1756]. *Blood Adv*. 2020;4(21):5580-5588.
185. Kekre N, Kim HT, Thanarajasingam G, et al. Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. *Haematologica*. 2015;100(9):1222-1227.
186. Schmid C, Labopin M, Schaap N, et al. Long-term results and GVHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. *Bone Marrow Transplant*. 2022;57(2):215-223.
187. Craddock C, Labopin M, Robin M, et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. 2016;101(7):879-883.
188. Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. *JAMA Oncol*. 2018;4(9):1245-1253.
189. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. *Nat Med*. 2020;26(12):1852-1858.
190. Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML. *Nat Rev Clin Oncol*. 2021;18(9):577-590.
191. Stein EM, Aldoss J, DiPersio JF, et al. Safety and efficacy of menin inhibition in patients with MLL-rearranged and NPM1 mutant acute leukemia: a phase 1, first-in-

- human study of SNDX-5613. *Blood*. 2021; 138(suppl 1):699.
192. Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. *Blood*. 2021;137(6):751-762.
 193. Wermke M, Kraus S, Ehninger A, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. *Blood*. 2021;137(22):3145-3148.
 194. Zeidan AM, DeAngelo DJ, Palmer J, et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. *Ann Hematol*. 2022;101(3):557-569.
 195. Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. *Blood*. 2020; 136(6):674-683.
 196. Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? *Cells*. 2020;9(10):2310.
 197. Récher C. Clinical implications of inflammation in acute myeloid leukemia. *Front Oncol*. 2021;11:623952.
 198. Padmanabhan A, Connelly-Smith L, Aquilino N, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. *J Clin Apher*. 2019;34(3):171-354.
 199. Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia: a systematic review and meta-analysis. *Transfusion*. 2020;60(10): 2360-2369.
 200. Stahl M, Shallis RM, Wei W, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. *Leukemia*. 2020;34(12):3149-3160.
 201. Ten Cate H, Leader A. Management of disseminated intravascular coagulation in acute leukemias. *Hamostaseologie*. 2021; 41(2):120-126.
 202. Fathi AT, DiNardo CD, Kline I, et al; AG221-C-001 Study Investigators. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 analysis of a phase 1/2 study. *JAMA Oncol*. 2018;4(8):1106-1110.
 203. Maertens JA, Girmenia C, Brüggemann RJ, et al; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. *J Antimicrob Chemother*. 2018;73(12):3221-3230.
 204. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. *Bone Marrow Transplant*. 2009;43(10):757-770.
 205. Ullmann AJ, Schmidt-Hieber M, Bertz H, et al; Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. *Ann Hematol*. 2016;95(9):1435-1455.
 206. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. *Transpl Infect Dis*. 2013; 15(3):219-232.
 207. Agarwal SK, DiNardo CD, Potluri J, et al. Management of venetoclax-ponatin interaction in acute myeloid leukemia patients: evaluation of dose adjustments. *Clin Ther*. 2017;39(2):359-367.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.